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Résumé 
Le facteur d'initiation de la traduction chez les eukaryotes eIF4E (4E) est un puissant 
oncogène en raison de sa capacité à faciliter l'export et/ou la traduction de certains 
transcripts, dont beaucoup sont eux-mêmes des oncogènes. 4E intéragit avec un grand 
nombre de protéines régulatrices dont la protéine 4E-T (pour 4E-Transporter). La capacité 
de 4E-T à modifier la localisation subcellulaire de 4E pourrait offrir un mécanisme 
permettant de modifier le potentiel oncogène d'une cellule. La surexpression de 4E-T dans 
des cellules d'ostéosarcome conduit à l’augmentation du nombre et de la taille des P-bodies, 
dans lesquels 4E colocalisent avec 4E-T mais pas avec la version tronquée 4E-T/Y30A. 
Cependant, les différentes expériences menées, permettant d’analyser les taux de 
transcription, la quantité de protéine, les profiles polysomiques ainsi que la distribution 
nucléo-cytoplasmique, montrent que la surexpression de 4E-T n'a pas d'effet sur la fonction 
de 4E. L'observation d’un enrichissement cytoplasmique et d’une charge réduite de 
ribosomes sur les transcripts codant les protéines cycline D1 et ODC (profile polysomique) 
dans la lignée 4E-T suggère un role de 4E-T dans la séquestration cytoplasmique de 
certains transcrips par un mécanisme qui reste encore à déterminer. 
Mots-clés : 4ET, eIF4E, P-body 
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Abstract 
The eukaryotic translation initation factor eIF4E (4E) is a potent oncogene due to its ability 
to facilitate export and/or translation of certain transcripts, many of which are, themselves, 
oncogenes.  4E has many protein-binding partners including the 4E transporter protein (4E-
T).  The ability to alter the subcellular localization of 4E via 4E-T could offer a mechanism 
by which to alter the oncogenic potential of a cell.  Overexpression of 4E-T in 
osteosarcoma cells leads to formation of larger and more numerous P-bodies that can 
effectively colocalize with 4E than either a vector control (E) or a less efficient 4E-binding 
version of 4E-T (Y30A).   However, the overexpression of 4E-T did not affect the 4E’s 
function as determined by examining global levels of transcription, polysome profile, 
cytoplasmic/nuclear distribution, or protein levels of most of the transcripts tested. The 
observation that there was cytoplasmic enrichment and reduced loading of ribosomes on 
cyclin D1 and ODC transcripts (polysome profile) in the 4ET line suggests a possible 4ET-
mediated cytoplasmic sequestration of certain transcripts by an as yet to be determined 
mechanism. 
 
Keywords : 4E-T, P-body, 4E 
  
v 
 
Table of contents 
Chapter 1.  General Introduction.......................................................................................... 12!
Transcript generation and movement in the eukaryotic cell ............................................ 12!
eIF4E ................................................................................................................................ 20!
Molecular basis for 4E mediated transformation ............................................................. 20!
Modes of Regulation of 4E .............................................................................................. 22!
Controlling the expression of 4E mRNA ..................................................................... 22!
Control of 4E through interactions with partner proteins ............................................ 22!
Controlling 4E activity by modulating its subcellular distribution .............................. 27!
4E-T.................................................................................................................................. 29!
P-bodies and Stress Granules ........................................................................................... 36!
Chapter 2. Creation of 4E-T overexpression cell lines ........................................................ 43!
Introduction ...................................................................................................................... 43!
Materials and Methods ..................................................................................................... 43!
Results .............................................................................................................................. 47!
Discussion ........................................................................................................................ 48!
Chapter 3. Overexpression of 4E-T causes the formation of processing bodies ................. 55!
Introduction ...................................................................................................................... 55!
Materials and Methods ..................................................................................................... 56!
Results .............................................................................................................................. 56!
Discussion ........................................................................................................................ 58!
Chapter 4.  4E-T overexpression relocalizes a proportion of 4E in U2Os cells. ................. 66!
Introduction ...................................................................................................................... 66!
Materials and Methods ..................................................................................................... 66!
Results .............................................................................................................................. 67!
Discussion ........................................................................................................................ 68!
Chapter 5.  Impact of 4E-T overexpression on 4E-SE-containing transcripts and the protein 
products of 4E-sensitive transcripts. .................................................................................... 72!
Introduction ...................................................................................................................... 72!
Materials and Methods ..................................................................................................... 72!
Results .............................................................................................................................. 76!
Discussion ........................................................................................................................ 77!
Chapter 6.  4E-T overexpression effect on polysome profile. ............................................. 91!
Introduction ...................................................................................................................... 91!
Materials and Methods ..................................................................................................... 92!
Results .............................................................................................................................. 93!
  
vi 
 
Discussion ........................................................................................................................ 95!
Chapter 7.  General discussion and Conclusion................................................................. 103!
Future directions............................................................................................................. 106!
Supplemental data .............................................................................................................. 111!
siRNA depletion of 4ET inhibits P-body formation in FaDu cells. ............................... 111!
Introduction .................................................................................................................... 111!
Materials and Methods ................................................................................................... 111!
Results ............................................................................................................................ 112!
Discussion ...................................................................................................................... 112!
 
  
vii 
 
List of tables 
Table 1.1.  Classes of eIF4E................................................................................................. 24!
Table 1.2.  Transcripts that contain a 4E-SE and/or are 4E-sensitive.................................. 25!
Table 1.3.  4E binding partners. ........................................................................................... 26!
Table 1.4.  4ET characteristics. ............................................................................................ 33!
Table 1.5. Protein components of SGs................................................................................. 38!
Table 1.6. Protein components of P-bodies. ........................................................................ 39!
Table 2.1.  Antibody concentrations used for indirect immunofluorescence. ..................... 51!
Table 2.2.  Flow cytometry data from BD FACSAria sorted pMSCV-infected U2Os cells.
...................................................................................................................................... 52!
Table 5.1. Western blot targets. ........................................................................................... 75!
Table 5.2. Primers and targets for RT-qPCR ....................................................................... 75!
Table 5.3.  RNA elements in transcripts tested. ................................................................... 90!
 
  
viii 
 
List of figures 
Figure 1.1 The central dogma of molecular biology showing some rate processes which 
affect cellular RNA and protein levels......................................................................... 18!
Figure 1.2. Preininitiation and translation initiation complex.............................................. 19!
Figure 1.3.  Cartoon of the 4E-T protein.............................................................................. 32!
Figure 1.4.   Amino acid sequence alignment for 4ET across species................................. 34!
Figure 1.5. Tissue distribution of 4ET mRNA in humans. .................................................. 35!
Figure 1.6.  Schematic overview of experimental strategy for construction of 
overexpression cell lines .............................................................................................. 42!
Figure 2.1.  4ET is overexpressed in Y30A and 4ET cell lines as compared to the E control. 
...................................................................................................................................... 52!
Figure 3.2.Western blot of Dcp1a. ....................................................................................... 62!
Figure 3.3.  Micrographs of Y30A cell line showing disappearance of P-bodies with 
increasing emetine treatment........................................................................................ 63!
Figure 3.4.  Micrographs of 4ET cell line showing disappearance of P-bodies with 
increasing emetine treatment........................................................................................ 64!
Figure 3.5.  Micrographs of E cell line untreated, and treated with emetine for 1 hour, 1.5 
hours, and 2 hours. ....................................................................................................... 65!
Figure  4.1. Overexpression of 4E-T relocalizes endogenous 4E. ....................................... 70!
Figure  4.2.  4E-T overexpression does not drastically alter the protein level or mRNA level 
of 4E. ............................................................................................................................ 71!
Figure 5.1.  Fractionation controls.. ..................................................................................... 86!
Figure 5.2.  RT-qPCR results for 4E-SE transcripts ............................................................ 87!
Figure 5.3.  RT-qPCR results for 4E-sensitive and 4E-SE containing 4E-sensitive 
transcripts.. ................................................................................................................... 88!
Figure 5.4. Western blot results for products of 4E-sensitive and 4E-SE containing 
transcripts. .................................................................................................................... 89!
Figure 6.1.  Polysome profiles and RNA of each faction. ................................................... 98!
  
ix 
 
Figure 6.2.  Superposition of polysome traces for 4ET and E. ............................................ 99!
Figure 6.3.  Tubulin data. ................................................................................................... 100!
Figure 6.4. Raw Ct data for inputs of 4E-SE containing transcripts.................................. 100!
Figure 6.5.  Raw Ct data for inputs of 4E-sensitive transcripts and 4E-SE containing 4E-
sensitive transcripts. ................................................................................................... 100!
Figure 6.6.  Transcript profiles for 4E-SE containing transcripts. ..................................... 101!
Figure 6.7. Transcript profiles for 4E-sensitive and 4E-SE containing 4E-sensitive 
transcripts. .................................................................................................................. 102!
Figure 7.1.  Models of potential interaction of 4ET and mRNA in P-bodies. ................... 109!
Figure S.1.  FaDu cells transfected with si4ET do not have P-bodies. .............................. 113!
  
x 
 
To the memory of my father 
  
xi 
 
Acknowledgements 
I thank Katherine Borden for giving me this project.  I thank all members of the 
Borden lab (past and present) as well as members of the IRIC community who have helped 
me with my studies.
 Chapter 1.  General Introduction 
This study explores the effect of overexpression of eukaryotic translation initiation factor 
transporter EIF4ENIF1 (referred to as 4E-T in this work) on its relationship with the 
eukaryotic translation initiation factor eIF4E (4E).  A review of the literature concerning 
RNA export and translation as well as the current knowledge to date about 4E and 4E-T 
follows. 
Transcript generation and movement in the eukaryotic cell 
The central dogma of molecular biology in its most general form states that DNA is 
transcribed to messenger RNA (mRNA) and mRNA is translated to protein (F. Crick, 1970; 
F. H. Crick, 1958) (Figure 1.1).  If we assume that proteins are the active species in a cell 
and that the variety and abundance of proteins within a cell is important in determining 
health versus disease status, then the pool of RNA available to be translated to protein 
becomes of prime importance.    The pool of RNA within a cell is regulated by rates of 
transcription, mRNA nuclear export, and mRNA sequestration (or in mathematical terms, 
where k= rate; RNA pool = kTranscription- kmRNA nuclear export – kmRNA degradation - kmRNA sequestration) (Figure 
1.1).  Crudely, protein abundance within a cell can be expressed as kTranslation – kProtein degradation  
(Figure 1.1). 
 
Transcription rate is influenced by promoter strength and presence of regulatory elements 
for the gene in question.  DNA is initially transcribed in the nucleus by RNA polymerase II 
to precursor mRNA.  Shortly after transcription initiation, a 7-methyl guanosine 
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dinucleotide cap structure (m7GpppN, where N is any nucleotide) is added to the 5’ end of 
the RNA.  Introns are contranscriptionally removed from the precursor mRNA, RNA 
editing occurs, and the cleavage and polyadenylation of the 3’ end take place.  A variety of 
RNA-binding proteins interact with the precursor mRNA during these processes and afford 
a level RNA quality control (known as RNA surveillance) within the nucleus (reviewed by 
Moraes, 2010).  While undergoing proper processing, the mRNA also needs to fold into a 
favorable tertiary structure—folding is thought to occur via the kinetic energy 
conformation-based model (Schroeder, Grossberger, Pichler, & Waldsich, 2002).  If there 
are errors in the nascent mRNAs and/or their tertiary structure, they may be subject to 
degradation via 3’to 5’ exosome complexes either in the nucleus or the cytoplasm. 
 
Export of mRNA from the nucleus to the cytoplasm is controlled in a process known as 
gatekeeping (reviewed by Dimaano & Ullman, 2004; Saguez, Olesen, & Jensen, 2005; 
Vinciguerra & Stutz, 2004). Gatekeeping occurs at the nuclear pore and works in at least 
two ways:  1) it restricts export of transcripts that are incompletely matured; and 2) it 
promotes export of mRNAs that are associated with the appropriate proteins.  Mammalian 
RNA export through nuclear pores can be facilitated by association with various RNA-
binding proteins depending on the type of RNA (as reviewed by Kohler & Hurt, 2007).  
tRNA export is mediated by Exp-t protein, while miRNA export is mediated by Exp-5.   
The assembly of CBC, PHAX and CRM1 aids snRNA export.  rRNA export involves the 
proteins Mex67, Mtr2, Arx1, Nmd3, and CRM1.  tRNA, miRNA, snRNA, and rRNA 
  
14 
 
export all require Ran GTPases.  mRNA export involves CBC, ALY/Yra1, TAP/Nex67, 
and p15/Mtr2.  The translation initiation factor eIF4E (4E) can also facilitate the export of 
certain mRNAs, which possess a specific secondary structure in their 3’ untranslated region 
(UTR).  A more detailed discussion about 4E’s export function follows in the eIF4E section 
of this introductory chapter. 
 
Aberrant transcripts must be removed in order to prevent translation of abnormal proteins 
(reviewed in Isken & Maquat, 2007).  In mammals, when an mRNA possesses a premature 
termination codon (PTC), nonsense-mediated decay (NMD) can occur.  Classical NMD 
requires a splicing event downstream from a PTC while fail-safe NMD requires a splicing 
event upstream of a PTC.  If the transcript lacks a termination codon, then non-stop decay 
can occur.  If the transcript causes translation elongation to stall, then and non-go decay can 
occur.   
 
Normal transcript can be removed via binding of microRNAs (miRNAs).  miRNAs are 
small, endogenous, non-coding ~22 nucleotide RNAs that regulate gene expression of 
approximately 60% of genes in the genome by interfering with translation or stability of 
target transcripts (reviewed in Jackson & Linsley, 2010).   They bind through partial 
complementarity, mostly involving an 8-nucleotide seed sequence to 3’ UTR of target 
mRNAs.  As the miRNAs do not require perfect complementarity for target recognition, a 
single miRNA may regulate multiple mRNAs.   
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Normal mRNA turnover helps the cell achieve its biochemical equilibrium.  Integration of 
physiological signals determines when a transcript is to be degraded.  Rate of degradation 
of a specific transcript is controlled by cis-acting elements in the mRNA and trans-acting 
factors that bind these cis elements. In this way, the specific RNA-binding proteins that 
interact with a given mRNA will affect the mRNA’s stability (and consequently 
abundance) in the cytoplasm.  Examples of cis elements include the AU-nucleotide rich 
elements (AREs) found in the 3’ UTRs of mRNAs (reviewed in Kedersha & Anderson, 
2002).  HuR and tristetrapolin protein (TTP) are examples of trans factors that bind to 
AREs.  HuR is a member of a superfamily of elav-related proteins that can bind AREs.  
HuR is predominantly nuclear, but shuttles between the nucleus and the cytoplasm.  When 
HuR is bound to an ARE, it stabilizes the mRNA.  In contrast, TTP is a predominantly 
cytoplasmic ARE binding protein that targets certain mRNAs (e.g. tumour necrosis factor-
!, granulocyte-macrophage colony-stimulating factor, and interleukin-3) for degradation.  
Interestingly, both HuR and TTP are found in both stress granules and processing bodies 
(P-bodies)—to be discussed in the P-bodies and Stress Granules section of this introductory 
chapter. 
 
Appropriate cytoplasmic localization of certain mRNAs for proper function represents 
another type of pre-translational mRNA quality control (Gray & Wickens, 1998; Isken & 
Maquat, 2007).  Transcript localization is important for the spatial regulation of genes 
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involved in protein secretion, synaptic plasticity, cell motility, and embryonic axis 
formation (reviewed in Holt & Bullock, 2009; Mohr & Richter, 2001).   Selection of 
mRNA destined for localization appears to be determined by binding of trans factors 
binding to cis-elements in the 3’ UTR (Mohr & Richter, 2001).  These ribonucleoprotein 
(RNP) complexes are linked to cytoskeletal elements (microfilaments or microtubules) 
along which the RNPs travel.  Molecular anchors are required to fix transcripts at their final 
subcellular destinations.  While in transit, the transcripts are translationally silenced.  Holt 
and Bullock (2009) suggest that transcript localization offers certain advantages over 
targeting protein product:  1) increased efficiency afforded by producing multiple protein 
molecules from a single mRNA molecule; 2) prevention of ectopic protein activation 
during translocation; 3) facilitating assembly of macromolecular protein complexes; and 4) 
decentralizing control of gene expression by permitting local control of translation on 
demand in response to a signal. 
 
The rate of ribosome loading onto the transcript is important in determining the overall 
protein abundance in a cell.  Eukaryotic translation involves initiation, elongation and 
termination.  Translation initiation mostly occurs via 4E in a cap-dependent manner 
(Sonenberg, 1988).   A schematic drawing of the elements involved in cap-dependent 
translation initiation is depicted in Figure 1.2.  Certain transcripts that possess complex 5’ 
UTRs appear to be more reliant on 4E for translation initiation—so-called 4E-sensitive 
transcripts (discussed in more detail in the 4E section).   
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Other translation initiation factors can either display increased or decreased expression 
and/or phosphorylation status changes in certain cancers (reviewed in Silvera, Formenti, & 
Schneider, 2010). Uncoupling of translation regulation from inhibition by cellular stresses 
such as hypoxia and nutrient deprivation is often seen in human cancers (reviewed in 
Silvera, et al., 2010).  Alterations in translation regulation can also be associated with 
specific types of cancer and/or different stages of disease or transformation.  
 
Cap-independent translation initiation can occur via internal ribosome entry sites (IRESs) 
(reviewed in Gray & Wickens, 1998; van der Velden & Thomas, 1999).  Other transcripts 
such as those encoding for certain ribosomal proteins and translation elongation factors 
make use of 5’ terminal oligopyrimidine (5’TOP) sequence for translation initiation (van 
der Velden & Thomas, 1999). 
 
 
Protein degradation is influenced by posttranslational modifications such as ubiquitiniation 
and sumoylation.  However, the focus of this M.Sc. work explores the observed effects of 
4ET overexpression on kmRNA nuclear export, kmRNA sequestration, and kTranslation for 4E target RNAs.  
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Figure 1.1 The central dogma of molecular biology showing some rate processes, which 
affect cellular RNA and protein levels. (adapted from (de Sousa Abreu, Penalva, Marcotte, 
& Vogel, 2009) 
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Figure 1.2. Preininitiation and translation initiation complex.  eIF2-GTP-tRNA = ternary 
complex.  eIF4A + eIF4E + eIF4G = eIF4F.  PABP = polyA binding protein.  40S + 80S = 
ribosome. 
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eIF4E 
The eukaryotic translation initiation factor eIF4E (4E) regulates gene expression post-
transcriptionally at the levels of mRNA translation and mRNA export (Culjkovic et al., 
2008; Culjkovic, Topisirovic, Skrabanek, Ruiz-Gutierrez, & Borden, 2005; Sonenberg & 
Gingras, 1998). It has recently been reported that there are 3 classes of 4E (Joshi, Cameron, 
& Jagus, 2004; Rhoads, 2009) a comparison of the 4E members is presented in Table 1.1).  
4E (human eIF4E-1) overexpression leads to oncogenic transformation in cell culture 
(Graff et al., 1995; Lazaris-Karatzas & Sonenberg, 1992) and tumour enlargement and 
increased metastases in xenograft mouse models (Ruggero et al., 2004).  Interestingly, a 
newly identified member eIF4E1b shows oocyte specificity and strong binding to the 4E 
transporter protein 4ET (Evsikov & Marin de Evsikova, 2009; Standart & Minshall, 2008; 
Villaescusa et al., 2006). Unlike the other classes of 4E, eIF4E1b acts a a translational 
repressor of dormant maternal mRNAs (Evsikov & Marin de Evsikova, 2009). 
 
Molecular basis for 4E mediated transformation 
The oncogenic potential of 4E arises from its biochemical functions: mRNA export, 
translation initiation, and potentially mRNA stability.  In the nucleus, 4E exports certain 
transcripts.  An approximately 50-nucleotide sequence denoted the 4E sensitivity element 
(4E-SE) is found in the 3’ UTR of transcripts whose export is effected by 4E (Culjkovic, et 
al., 2005).  In both the nucleus and the cytoplasm, 4E associates with the 5’ end of mRNAs 
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via the cap structure (Sonenberg, 1988). In the cytoplasm, 4E, along with eIF4A and 
eIF4G, forms the 5'-cap binding protein complex and promotes cap-dependent translation 
initiation (Rhoads, 1988; Rozen et al., 1990)(Figure 1.2).  Translation efficiency differs 
between mRNAs depending on the complexity of the secondary structure in their 5' UTRs. 
4E overexpression increases translational efficiency of mRNAs with structured 5’ UTRs.  
These transcripts are considered 4E sensitive (4E-sensitive transcripts or 4E-STs).  
Examples of 4E-SE containing transcripts and 4E-STs are presented in Table 1.2. 
 
Recent studies describe 4E as a focal point in an "RNA regulon" that governs cell 
proliferation and survival (Culjkovic, Topisirovic, & Borden, 2007).  A regulon is an 
organizational unit that synchronizes the expression of specific genes post-transcriptionally 
that are involved in a common pathway (Keene & Lager, 2005).  4E coordinately promotes 
both the export of mRNA and translation of several genes involved in cell cycle 
progression and survival.  The coordination occurs via co-factors binding elements in the 3' 
and 5' UTRs.  Families of 4E-STs with similar secondary structures will be coordinately 
regulated.   
 
4E is a clinically relevant oncogene which is elevated in 30% of cancers including breast 
cancer, colon cancer, head and neck squamous cell carcinoma, and several types of 
leukemia and lymphoma (Culjkovic & Borden, 2009; Graff & Zimmer, 2003). 4E is a 
diagnostic marker for metastases, increased tumour invasion and is correlated with poor 
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prognosis. Targeting 4E in leukemia patients led to clinical benefit (reviewed in (Assouline 
et al., 2009; Graff & Zimmer, 2003).  
 
Modes of Regulation of 4E 
4E can be regulated at the level of its transcription, at the level of its subcellular 
localization, and at the level of its interaction with other proteins. 
 
Controlling the expression of 4E mRNA 
In some human 4E-related cancer cases, the elevated level is due to gene amplification of 
4E (Sorrells, Meschonat, Black, & Li, 1999).  In other cases, increased stability of the 4E 
transcript leads to its observed increased level (e.g. stabilization by the protein HuR 
(Topisirovic, Siddiqui, & Borden, 2009)). 
 
Control of 4E through interactions with partner proteins 
4E activity can be modulated by the presence or absence of 4E binding proteins. Proteins 
that interact with 4E fall into three broad categories (refer to Table 1.3):  1) proteins 
containing a conserved eIF4E-binding site (YXXXXL", where X is any residue and " is a 
hydrophobic residue (Mader, Lee, Pause, & Sonenberg, 1995)) to interact directly with the 
dorsal surface of 4E; 2) proteins containing a RING domain (such as promyelocytic 
leukemia protein (PML) (Volpon, Osborne, Capul, de la Torre, & Borden, 2010)); and 3) 
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proteins that do not contain YXXXXL" or a RING domain (such as invasion inhibitory 
protein 45 (IIp45) (Borden lab, unpublished)). 
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Table 1.1.  Classes of eIF4E.  (adapted from (Evsikov & Marin de Evsikova, 2009; Joshi, et 
al., 2004; Rhoads, 2009)  
 Class I Class IB Class II Class III 
NM* NM_001968.3 NM_001099408.1 NM_004846.2 NM_173359.4 
Chromosomal 
location* 
4q21 5q35.2 2q37.1 3p14 
mRNA length* 4749 bp 1974 bp 1014 bp 6185 bp 
Amino acid length* 217 residues 242 residues 245 residues 118 residues 
Protein weight* 25 kDa 27.4 kDa 28 kDa 13.2 kDa 
Cap binding 
tryptophans and/or 
substitutions** 
W43 
W56 
W73 
W103 
W113 
W130 
W160 
? W43#Y, F, L 
W56#Y, F 
 
W56#C, Y 
Tissue distribution* 
(mRNA) 
Ubiquitous, most 
in testes and 
muscle 
growing oocyte Ubiquitous, most 
in testes 
Heart, skeletal 
muscle, lung, and 
spleen 
Ability to bind cap Yes weak Yes Yes (ability to 
discriminate between 
GTP and m7GTP < 
Class I) 
Ability to bind eIF4G Yes weak No Yes 
Ability to bind 
4EBPs 
Yes Unknown; binds 
4ET strongly 
No Yes 
Ability to rescue 
eIF4E- S. cerevisiae 
Yes unknown No No 
Phylogenetic 
distribution 
All eukaryotes tetrapods All metazoans Chordates 
Examples C. elegans IFE-1 
C. elegans IFE-2 
D. rerio eIF4E1-B 
S. pombe eIF4E-2 
X. laevis eIF4E-1B 
M. musculus 
eIF4E1b 
 
A. thaliana nCBP 
C. elegans IFE-4 
D. melanogaster 
4EHP 
H. sapiens 4E-HP 
M. musculus 
eIF4E-2 
M. musculus eIF4E-3 
*in humans 
**tryptophan position is relative to eIF4E-1 in humans 
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Table 1.2.  Transcripts that contain a 4E-SE and/or are 4E-sensitive. (adapted from 
(Culjkovic, Topisirovic, Skrabanek, Ruiz-Gutierrez, & Borden, 2006) 
mRNA containing 4E-SE 4E-sensitive transcript 4E-sensitive transcript 
containing 4E-SE 
Cyclin D1 VEGF ODC-1 
Cyclin E1  Cyclin B1 
Cyclin A2  Pim-1 
Mdm2  cMyc 
Nbs1   
Fbox1   
CGGbp1   
P54nrb/NONO.1   
Selenoprotein S   
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Table 1.3.  4E binding partners. (adapted from (Rhoads, 2009). 
Binding motif Sequence (if known) Name 
YXXXXL" LLLDKRLRSEC CYFIP1 
 YDRKFL 4EBP1 
 YVDSFLL HOXA9 
 YAPTPLL PRH 
 YDREFLL EIF4G 
 YSNPDLV EMX2 
 YTKKELL 4ET 
 YFWPLLV LRPPRC 
 YIPPHLR DDX3 
 YTIDELF p20 
 TEADFLL Maskin 
 YRKEELE Lipoxygenase 2 
 YTRSRLM Cup 
 YIRPYLP Bicoid 
 RLQSTLKRIG BTF3 
 LKLPFLK and YEAVELL Gemin5 
 YPTEKGL, YQIDKLVKT, and 
YVPPRLV Neuroguidin 
AA 59-93 of TuMV VPg  Viral VPg proteins 
  PGL-1 
NHL domain  Brat 
RING domain  PML 
  Z 
Unknown  IIP45 
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Homeoproteins that contain the conserved 4E-binding motif are tissue-specific factors that 
modulate 4E activity.  PML and Z RING proteins interact with eIF4E via their RING 
domains leading to a 100X reduction in affinity of 4E for the m7G cap (Cohen et al., 2001; 
Kentsis et al., 2001; Volpon, et al., 2010). 
 
The best-characterized regulator of 4E is 4E-binding protein 1 (BP1).  BP1 uses its 
YXXXXL" site to bind 4E and prevent its access to eIF4G and the rest of the translation 
machinery.  Phosphorylation of BP1 reduces its interaction with eIF4E that leads to 
increased translation activity of 4E.  BP1 and phospho-BP1 levels are modulated in human 
cancers including M4 AMLs.  BP1 levels can be highly elevated in AML (Borden lab, 
unpublished) and breast cancers (Armengol et al., 2007) which is thought to reflect a 
change in translational status resulting from a change in local environment from high 
oxygen to anoxic. 
 
Controlling 4E activity by modulating its subcellular distribution 
As stated above, 4E is found both in the nucleus and in the cytoplasm.  In the cytoplasm, 
4E is found not only with actively translated transcripts, but also in processing bodies (P-
bodies) (Andrei et al., 2005).  P-bodies may act as a temporary storage depot for RNAs but 
may also be the site of RNA degradation.  It is thought that the presence of 4E with RNAs 
in P-bodies is associated with a sequestration of such mRNAs. 
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Re-distribution of 4E can occur by multiple methods.  Transduction of I$B-SR leads to re-
organization of 4E by reducing the amount of 4E in the nucleus and increasing its amount 
in the cytoplasm as well as re-organization of remaining eIF4E nuclear bodies into 
structures that are morphologically indistinguishable from normal cells (Topisirovic, 
Guzman et al., 2003).  I$B-SR transduction also leads to reduced 4E dependent mRNA 
export.  Treatment with the m7G cap analogue, m7GpppG leads to disruption of 4E nuclear 
bodies and re-distribution of 4E in the cytoplasm (Cohen, et al., 2001; Dostie, Lejbkowicz, 
& Sonenberg, 2000).  A chemical analogue of the m7G cap, ribavirin, also leads to an 
increased fraction of 4E in the cytoplasm and reduced amount of 4E-dependent mRNA 
export (Assouline, et al., 2009; Kentsis et al., 2005; Tan, Culjkovic, Amri, & Borden, 
2008).   Some AML patient specimens can have mislocalized 4E where it is found 
primarily in the nucleus (Assouline, et al., 2009; Topisirovic, Culjkovic et al., 2003).  Upon 
ribavirin treatment, these patients display a large fraction of 4E in the cytoplasm which is 
correlated with a positive response (Assouline, et al., 2009). 
 
There are several endogenous proteins that can modulate the localization of 4E.  These 
proteins include PRH, LRP and 4E-T (Ferraiuolo et al., 2005; Topisirovic, Guzman, et al., 
2003; Topisirovic et al., 2009).  4E-T uses its conserved 4E-binding site to interact directly 
with the dorsal surface of 4E.  Overexpression of 4E-T leads to relocalization of the 
majority of nuclear 4E to the cytoplasm, where a subset is founding processing bodies (P-
bodies).  The molecular mechanism for this re-distribution is as yet unknown. 
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4E-T 
Dostie et al (2000) first described the 4E transporter protein 4E-T as a nucleocytoplasmic 
shuttling protein that contains a 4E-binding site, one bipartite nuclear localization signal 
and two leucine-rich nuclear export signals (see Figure 1.3). A number of transcripts for 
4ET have been reported (summarized in Table 1.4).  4ET amino acid sequence is highly 
conserved across chordate species as is its 4E binding motif (boxed region) (Figure 1.4), 
which suggests that 4ET function and ability to bind 4E is evolutionarily conserved (and 
therefore of some functional significance). No 4ET orthologue has been identified in yeast.  
4E forms a complex with the importin !" heterodimer only in the presence of 4E-T. Dostie 
et al (2000) suggest that 4E-T mediates the nuclear import of 4E via the importin !" 
pathway by a piggyback mechanism. 
 
At steady state, 4E-T is predominantly cytoplasmic and appears to be concentrated in P-
bodies. Ferraiuolo et al (2005) demonstrated that 4E-T colocalizes with mRNA decapping 
factors in bona fide P-bodies. 4E-T controls mRNA half-life, because its depletion from 
cells using short interfering RNA increases mRNA stability. The 4E-T binding partner, 4E, 
also localized to P-bodies when 4E-T was overexpressed. Ferraiuolo et al (2005) suggest 
that 4E-T interaction with 4E is a priming event in inducing messenger ribonucleoprotein 
rearrangement and transition from translation to decay. 
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4E-T appears to be involved in hypoxia-induced mRNA translation inhibition (Koritzinsky 
et al., 2006).  Hypoxia inhibits mRNA translation initiation biphasically via two distinct 
pathways: the first phase occurs rapidly, reaching a maximum at 1–2 h and is due to 
phosphorylation of eIF2!; continued hypoxic exposure activates a second, eIF2!-
independent pathway that maintains repression of translation. This phase is characterized 
by disruption of eIF4F and sequestration of 4E by its inhibitors 4E-BP1 and 4E-T.  
 
 
Tissue distribution of 4ET mRNA from microarray studies is summarized in Figure 1.5 
from data found at www.biogps.gnf.org.  The dataset is an atlas of tissue expression 
(GeneAtlas) on an Affymetrix U133A array, using the gcrma algorithm to process the data.  
The Y-axis represents normalized, background-subtracted, and summarized (probes to 
probeset) intensity of the probeset.  Highest expression of 4ET transcript appears to be in 
the testis, dendritic cells, retina, brain, and various blood cell lineages.  No 4ET knockout 
mouse exists, but several knockout cell lines are available (MGI and International Mouse 
Knockout Consortium).  In mice, P-bodies are also found in oocytes but they disappear 
upon oocyte growth while subcortical ribonucleoportein particle domains (SCRDs) form 
((Flemr, Ma, Schultz, & Svoboda, 2010; Swetloff et al., 2009).  If 4ET expression is similar 
to that of another P-body protein GW182, then it is variably but widely expressed in 
species (Eystathioy et al., 2002). 
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4ET shows different levels of phosphorylation in the cell cycle (Pyronnet & Sonenberg, 
2001).  4ET becomes more phosphorylated and shows decreased binding to 4E in mitosis.   
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Figure 1.3.  Cartoon of the 4E-T protein.   
4E-T is shown with the N-terminus on the left and C-terminus on the right.  Numbers 
denote amino acid positions.  Putative phosphorylated residues are shown.  The EIF4E-T 
domain is highlighted (domain defined by NCBI).  NLS denotes nuclear localization signal.  
NES denotes nuclear export signal.  The 4E-binding site is situated at amino acid positions 
30-36.  Y at position 30 when mutated to A partially abrogates 4E-binding.   
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Table 1.4.  4ET characteristics. 
Feature  
NM* 019843.2 
Chromosomal position* 22q11.2 
Refseq alternate transcripts # exons # amino acids Protein weight (kDa) 
EIF4ENIF-001 17 811 88.2 
EIF4ENIF-002 19 985 108.2 
EIF4ENIF-003 19 985 108.2 
EIF4ENIF-005 17 961 105.5 
EIF4ENIF-006 5 188 21.4 
EIF4ENIF-008 4 63 7.2 
EIF4ENIF-009 4 63 7.2 
EIF4ENIF-012 7 239 26.0 
EIF4ENIF-201 18 961 105.5 
EIF4ENIF-202 18 685 108.2 
EIF4ENIF-203 9 63 7.3 
*human; 4ET constructs for this work are based on NM019843.2 to produce a HA-tagged 
protein of approximately 140 kDa. 
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Figure 1.4.   Amino acid sequence alignment for 4ET across species.  Homo sapiens = 
humans, Mus musculus = mouse, Rattus norvegicus = rat, Pan troglodytes = chimpanzee, 
Canis familiaris = dog, Bos taurus = cow, Gallus gallus= chicken, Danio rerio = zebrafish 
Boxed region represents 4E binding motif. 
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Figure 1.5. Tissue distribution of 4ET mRNA in humans.  (from http://biogps.gnf.org) 
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P-bodies and Stress Granules 
As a consequence of stress-induced translational silencing, polysomes disassemble and the 
circular polyadenylated mRNA protein complexes (mRNPs) can either form stress granules 
(SGs) or processing bodies (P-bodies, also known as GW182 or GW bodies or Dcp1 
bodies) (reviewed in (Anderson & Kedersha, 2009; Kedersha & Anderson, 2007).  Both P-
bodies and SGs share certain proteins (boldfaced type genes in Tables 1.5 and 1.6).  In 
metazoans, both SGs and P-bodies contain miRNA silencing elements (Leung & Sharp, 
2006). 
 
SGs and P-bodies differ in several ways:  1) only P-bodies are present in actively growing 
cells; 2) SG but not P-body assembly requires stress-induced phosphorylation of eIF2! 
(Kedersha et al., 2005); 3) SGs contain translational proteins such as eIF3, eIF4A, eIF4G, 
polyA-binding protein 1 (PABP-1), and small ribosomal subunits; 4) P-bodies contain 
mRNA decay proteins (refer to Table 1.6). 
 
Multiple proteins are found within SGs and P-bodies (Tables 1.5 and 1.6 respectively). SGs 
can be roughly classified into three groups:  stalled translation complexes; proteins 
involved in translational silencing or mRNA stability; proteins which regulate splicing, 
RNA editing and RNA localization.  P-body components can also grouped into three 
classes:  RNA-binding proteins and translational repressors; proteins involved in nonsense-
mediated decay (NMD); and proteins affecting viral function.  
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The components of P-bodies and SGs are continually exchanging with the cytoplasm 
(Andrei, et al., 2005; Gilks et al., 2004; Kedersha, et al., 2005; Z. Yang et al., 2004).  SGs 
and P-bodies are also mobile cytoplasmic structures, which transiently interact with one 
another (Kedersha, et al., 2005).  Kedersha observed that SGs were relatively immobile but 
fluid in shape whereas P-bodies were fixed in shape but very mobile with intermittent 
interaction with SGs.  The interaction between SGs and P-bodies allows for the possible 
transfer of mRNPs. 
 
In yeast, P-bodies increase in size but decrease in number with increasing cell density 
(Teixeira, Sheth, Valencia-Sanchez, Brengues, & Parker, 2005).  P-body mRNAs in yeast 
can leave and re-enter the polyribosome pool (Brengues, Teixeira, & Parker, 2005).  In 
HeLa cells, P-bodies display cell cycle related changes:  they assemble in G1, are small in 
early S phase and become larger during late S and G2 phases, and disassemble prior to 
mitosis (Z. Yang, et al., 2004).  Yang et al. (2004) also found that P-bodies are also larger, 
brighter, and more numerous in proliferating cells. 
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Table 1.5. Protein components of SGs. (adapted from (Kedersha & Anderson, 2007)(genes 
in boldfaced type are also present in P-bodies) 
Function Protein name 
RNAi slicer Ago2 
Antiviral response APOBEC3G 
Translation Ataxin-2 
Cell growth Caprin-1 
mRNA silencing CPEB 
Unknown DIS1 
Translation eIF3 
Translation 4E 
Translation eIF4G 
Translation FAST 
Translation FMRP and FXR1 
RNA decay FBP and KSRP 
Ras signaling G3BP 
RNA stability HuR 
Signaling IP5K 
Development Lin28 
Transposon LINE 1 ORF1p 
Splicing MLN51 
Translation, stability PABP-1 
mRNA decay RCK 
Adhesion Plakophilin 
mRNA decay PMR1 
mRNA silencing Pumilio 2 
mRNA silencing Rap55 
Transcription Rpb4 
Transcription SRC3 
mRNA silencing Staufen 
RNP assembly SMN 
mRNA silencing TIA-1 and TIAR 
Signaling TRAF2 
mRNA decay TTP and BRF-1 
Cold-shock RNA binding protein YB-1 
localization ZBP1  
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Table 1.6. Protein components of P-bodies. (adapted from (Eulalio, Behm-Ansmant, & 
Izaurralde, 2007). (genes in boldfaced type are also present in SGs) 
Function Protein name Organisms 
5’#3’ exonuclease XRN1 
Kem1 
Human, mouse 
S. cerevisieae 
miRNA pathway GW182 
AIN-1 
Human, D. melanogaster 
C. elegans 
Decapping enzyme DCP2 
DCAP-2 
Human, D. melanogaster 
C. elegans, S. cerevisiae 
Decapping enzyme subunit DCP1 
DCAP-1 
Human, D. melanogaster, C. elegans 
S. cerevisieae 
Decapping co-activator Hedls 
Ge-1 
Human 
D. melanogaster 
Decapping co-activator CG5208 
Pat1 
Pat1b 
D. melanogaster 
S. cereviseae 
Human 
Decapping co-activator  EDC3 (LSm16) Human, D. melanogaster, S. cerevisiae 
Decapping co-activator complex  LSm1-7 Human, S. cereviseae 
Predicted decapping co-activator RAP55 (LSm14) Human 
Decapping co-activator, translation regulator RCK/p54 
Me31B 
CGH-1 
Dhh1 
Human 
D. melanogaster 
C. elegans 
S. cereviseae 
Translation initiation factor 4E Human, rat 
Translation repression 4E-T Human 
NMD SMG7 Human 
NMD SMG5 Human 
NMD UPF1 
Nam7 
Human 
S. cereviseae 
NMD UPF2 S. cerevisiae 
NMD UPF3 S. cerevisiae 
siRNA and miRNA pathways Argonaute 
proteins 
Human, D. melanogaster, C. elegans 
Deadenylation CCR4-CAF1-
NOT complex 
Human, S. cerevisiae 
Translation regulator CPEB Human 
Fas-activated Ser/Thr phosphoprotein FAST Human 
ARE-mediated mRNA decay TTP Human 
Double-stranded RNA-binding protein,  
mRNA localization 
Staufen D. melanogaster 
RNA-binding protein, decay of mitochondrial 
porin mRNA 
Rbp1 S. cereviseae 
RNA polII component Rbp4 S. cereviseae 
Suppressor of decapping defects Sbp1 S. cereviseae 
SMN complex component involved in U 
snRNPs assembly 
Gemin5 Human 
Stress-induced regulatory subunit of Dcs1 Dcs2 S. cereviseae 
Deoxycytidine deaminase with antiviral 
activity 
APOBEC3G, 
APOBEC3F 
Human 
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Rationale and Relevance:   
4E has been validated as a cancer target in myeloid leukemia  by our lab in collaboration 
with several hospitals (Assouline, et al., 2009).  The ability to reduce the oncogenic effects 
of 4E is a potential avenue for cancer therapy.  Therefore an understanding of how to 
manipulate 4E’s subcellular localization via 4E-T could be of therapeutic benefit to 
leukemia. 
 
Hypothesis:   
4E-T simultaneously modulates the activities of 4E in the nucleus (mRNA export), in the 
cytosol (translation), and in P-bodies (mRNA stability/sequestration) thereby 
reprogramming the proteome of the cell.   
 
Aims:  
i) Determine the effects of 4E-T on 4E-mediated mRNA export, translation activity, 
and sequestration in P-bodies;  
ii) Determine if the effects of overexpression of 4E-T are restricted to 4E-STs. 
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Scientific approach and expected outcomes:   
The approach taken was to establish stable U2Os cell lines overexpressing 4E-T and a less 
efficient-4E interacting form of 4E-T (Y30A mutant) as well as a vector control and 
perform various analyses using these cell lines (see Figure 1.3).   
 
Changes in 4E activity and localization as a function of 4E-T levels were monitored by 
Western blot, RT-qPCR, and indirect immunofluorescence microscopy. The ability of 4E-T 
to modulate the 4E-mediated nuclear export of 4E-SE containing transcripts was assessed 
using subcellular fractionation and RT-qPCR.   Translational efficiency of these 4E-SE 
transcripts was examined by polysomal analysis and RT-qPCR.   
  
This proposal will investigate the effects of 4E-T mediated relocalization of 4E and 
whether its biochemical and biological functions are related to its physiological activities in 
oncogenic transformation.  Elucidating the mechanisms involved in 4E control will 
contribute to our understanding of 4E-mediated oncogenesis.  This information may 
eventually facilitate the development of novel therapaeutic approaches for malignancies 
with disregulated 4E activity. 
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Figure 1.6.  Schematic overview of experimental strategy for construction of 
overexpression cell lines.   
WB = Western blot, qPCR = reverse transcription quantitative PCR, MeOH= methanol, IF 
= indirect immunofluorescence. 
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Chapter 2. Creation of 4E-T overexpression cell lines 
Introduction 
In order to test the hypothesis that the manipulation of 4E-T protein levels could alter the 
subcellular localization and potentially the function of 4E, it was imperative to construct a 
cell line that reliably overexpressed 4E-T.   
 
After several attempts at transient overexpression and clonal selection strategies, I 
proceeded with a murine stem cell virus (MSCV) retroviral expression strategy to establish 
overexpressing cell lines.    The strategy for construction of the overexpression cell lines is 
shown in Figure 1.4.  The cell lines overexpressed either: 1) wild type version of 4ET 
(4ET); 2) a reduced 4E-binding version of 4ET (Y30A); or an empty vector control (E).  
4ET and Y30A were triple HA-tagged at their N-terminus.  All constructs contained a GFP 
cassette to allow for GFP-sorting post integration to select for transduced cells. 
 
Materials and Methods 
 
Constructing the 4ET overexpression cell line  
293 GPG cells  (gift from the Roux lab) were used to generate amphotropic retroviruses to 
infect human osteosarcoma cell line U2Os  (ATCC # HTB-96) using the constructs 
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pMSCVY30A, pMSCV4ET, and pMSCVE (plasmids described in Dostie et al., 2000; gift 
from Sonenberg lab, McGill).   Briefly, 293 GPG cells grown in DMEM + 10% FBS + 
Penicillin/Streptomycin (all from Gibco) were transfected with 4 µg of construct using 
FuGENE 6 (Roche Applied Science) as per manufacturer’s protocol.  The next day, 293 
GPG cells were washed 2 X 3ml PBS and then grown overnight in 8 ml DMEM + 10% 
FBS + penicillin/streptomycin. Supernatant was collected 24 hrs and 48 hours post 
transfection and filtered (45 µm filter) to infect U2Os cells in the presence of polybrene 
(Sigma #H-9268; 4 µg/ml final concentration).  Infected U2Os cells were allowed to grow 
to confluence and then split 1:3.  As all constructs contained a GFP cassette, GFP positive 
cells were collected by FACS  (IRIC Flow Cytometry Platform using the BD FACSAria 
Cell Sorter) to establish the overexpression cell lines. 
 
Total protein lysate collection 
Cells were grown to approximately 90% confluence and collected by trypsinization and 
washed 2X with PBS (pH 7.2; centrifuged 2000 X g 5 minutes, 4 oC). Cell pellets were 
lysed in RIPA buffer + KKM (peptstain A (1 mg/ml), aprotinin (2 mg/ml), leupeptin (1 
mg/ml), phenanthroline (1mg/ml), and benzamidine (1.6 mg/ml)) and sonicated (Sonic 
Dismembrator Model 100 (Fisher Scientific) power 3; 1 pulse).  Lysed cells were 
centrifuged (12000 rpm, 4oC, 20 minutes) and supernatant quantified by bicinchoninic acid 
(BCA) assay (Thermo Scientific) using the absorbance at 562 nm (Ultrospec 2100 pro 
UV/visible spectrophotometer, GE Healthcare).   
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Western blot 
12% SDS resolving PAGE gels and 4% stacking gels were used.   Gel running conditions 
were 92 V for 17 minutes and then 192 V for 57 minutes.  20-80 µg of protein lysate were 
loaded per sample (equal amounts for each gel).  Gels were electroblotted (Biorad) to 
PVDF membrane (Thermo Scientific) overnight at 4oC in 1X Transfer buffer at a constant 
current of 200 mA.  Membranes were blocked in 5% milk TBST at room temperature for 1 
hour.  Membranes were incubated with primary antibody (1:500 4ET (Abnova  
H00056478-B01); 1:500 HA (mouse, Santa Cruz F-7 SC-7392) ; 1:5000 Actin (Sigma 
A54411)) overnight at 4 oC with rotation.  Membranes were washed (3X TBST, 1X TBS, 
10 minutes at room temperature with agitation), incubated with secondary antibody (1:5000 
ECL-anti-mouse IgG HRP-linked (GE Healthcare)) for 1 hour at room temperature, and 
washed again (as described previously).  ECL reagent (SuperSignal West Pico, Thermo 
Scientific) was prepared as per manufacturer’s specifications and applied to membranes.  
Membranes were exposed to X-ray film (AGFA Radiomat B plus full blue, Agfa) and 
developed in Kodak X-OMAT 2000A processor (Kodak).   
 
RNA collection 
Cells were grown to approximately 90% confluence, washed 2X with PBS and lysed with 
TRIzol (Invitrogen).  RNA was collected as per manufacturer’s specifications and 
resuspended in DEPC dH2O. 
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RT-PCR and qPCR 
RNA was quantified (Nanodrop 2000c; Thermo Scientific).  RNA was DNAse treated 
(Turbo DNAse kit AM 2339, Ambion) and 100 ng of DNased RNA was used to construct 
cDNA (random hexamers, MMLV; Invitrogen) using manufacturer’s protocol.  
Quantitative PCR (EXPRESS SYBR GreenER qPCR Supermix universal, Invitrogen) was 
conducted on ABI StepOne Plus real time PCR System (Applied Biosystems).  Primers for 
4E-T are (forward 5’AGACCTTGAGTGCCGTAACCAACA3’; reverse 
5’ATGGCTTTCAAGGTTTCGGCTGAC3’).  Primers for actin are (forward 5’ 
GCATGGAGTCCTGTGGCATCCACG3’; reverse 5’ 
GGTGTAACGCAACTAAGTCATAG3’).  Relative expression of mRNA is given as log2 
of 2-%%Ct values. 
 
Indirect Immunofluoresence 
Cells were grown on acid cleaned glass coverslips (Fisher Scientific).  Coverslips were 
washed 3X PBS (pH 7.2); quenched (50 mM ammonium chloride in PBS) 10 minutes at 
room temperature, air dried, fixed in 100% methanol (-20oC, 10 minutes), then blocked 
(10% FBS, 0.1% Tween) for 30-60 minutes at room temperature.  Coverslips were 
incubated with primary antibody in blocking buffer at 4oC overnight. Conditions for single 
and double staining are presented in Table 2.1. Coverslips were washed (3X 5 minutes 
PBS, room temperature), incubated with secondary antibody at room temperature in the 
dark for 60 minutes (Table 2.1); washed (3X 5 minutes PBS room temperature, in the dark), 
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air-dried, and mounted with DAPI (Vectorshield mounting medium for fluorescence with 
DAPI, Vector Laboratories).  Fluorescence micrographs from several fields were observed 
at 100X optical magnification with 2X digital zoom on a laser scanning confocal 
microscope (100X objective and numerical aperture 1.4; Zeiss LSM510, IRIC Bio-imaging 
Platform).  The blue channel was converted to green using the LSM510 software version 
3.2 (Carl Zeiss, Inc). 
 
Results 
 
Establishment of overexpression cell lines 
Post-infection, GFP-positive U2Os cells were obtained for the establishment of each of the 
overexpression cell lines (55.4% GFP-positive pMSCVY30A cells, 88.6% GFP-positive 
pMSCV4ET cells; and 99.6% GFP-positive pMSCVE cells, Table 2.2).   
 
GFP-positive cells were tested for their ability to overexpress HA (by Western blot) and 
4E-T (by Western blot and RT-qPCR).  Both Y30A and 4ET cell lines overexpress HA and 
4E-T protein as compared to the vector (E) control (Figure 2.1A).  The overexpression of 
mRNA for 4ET is observed by RT-qPCR for 4E-T in Y30A and 4ET as compared to E 
(Figure 2.1B).  There are some smaller protein products (both HA and 4ET) seen in the 
Western blot in Y30A and 4ET as compared to E. 
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Phenotype of overexpression cell lines 
Both the Y30A and 4ET cell lines displayed HA-positive cytoplasmic puncta (Figure 2.2A) 
and 4E-T positive cytoplasmic puncta (Figure 2.2B). 
 
The overexpressed 4E-T protein seen in the 4E-T overexpression and Y30A overexpression 
cell lines also expresses HA (Figure 2.3) and colocalizes in cytoplasmic puncta.  The E cell 
line does not show overexpression of 4E-T nor does it show colocalization of 4E-T and HA 
signal (compare E line to Y30A and 4E-T in Figure 2.3). 
 
Discussion 
 
The presence of GFP-positive U2Os cells post infection suggest that the retroviral strategy 
to create overexpression cell lines using the pMSCV constructs was successful. The 
characterization of the GFP-positive cells suggests that Y30A and 4ET overexpress mRNA 
for 4E-T (Figure 2.1B) that is translated into HA-tagged versions of 4E-T (Figure 2.1A and 
2.2) that manifest themselves as cytoplasmic foci (Figure 2.3).  Quantification of the level 
of protein overexpression would require reanalysis of Western blots with densitometry 
software.  The observation of cytoplasmic 4E-T positive foci is consistent with previously 
reported 4E-T overexpression cell systems (Dostie, Ferraiuolo, Pause, Adam, & Sonenberg, 
2000; Ferraiuolo, et al., 2005; Rong et al., 2008; Borden lab, unpublished).   
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The observation that the level of 4ET overexpression is higher in the 4ET line as compared 
to the Y30A cell line (in this derivation of the overexpression cell lines and previous 
derivations of overexpression cell lines using different overexpression vectors) is curious 
especially given that the construct design (e.g. vector backbone and promoter) were 
identical.  It is possible that the cells do not tolerate the Y30A variant of 4ET as well as 
wild type version of 4ET and so “adapts” to reduce the level of Y30A to “tolerable” levels.  
The total level of 4ET transcript appears to be 22X higher and 8X higher for 4ET and 
Y30A respectively as compared to E (Figure 2.1B).  Therefore, the introduced Y30A could 
be “silenced” at the level of transcriptional initiation or at the level of mRNA stability.  In 
the case of silencing at the level of transcriptional initiation, it could be that Y30A is either 
integrating into heterochromatic region of the genome more often than the 4ET construct or 
that the site of its integration is more prone to epigenetic silencing (e.g. DNA methylation).  
It is also possible that the transcript of Y30A is more rapidly degraded than the 4ET 
transcript.  Polysome analysis of 4ET transcript in the 4ET, Y30A, and E lines would 
establish whether or not the transcripts were behaving differently with respect to loading of 
ribosomes.   
 
The lower protein bands seen in the Western blots for 4ET and HA in the Y30A and 4ET 
cell lines that are not observed in the E line are not likely to be products of alternative 
transcripts (Table 1.4) as the introduced construct is based on 4ET cDNA.  The smaller 
protein 4ET/HA positive protein products of 4ET and Y30A are probably protein 
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degradation products (Figure 2.1A).  Collection of lysates in the presence of a proteasome 
inhibitor would resolve whether these smaller products are degradation products.   
 
The presence of some HA-signal that does not colocalize with 4E-T in both Y30A and 4ET 
is unexpected (Figure 2.2A).  Since there is HA signal in the nucleus in these cell lines, I 
suggest that this HA-staining is artefactual and due to the HA antibody used in the double 
stain cross reacting non-specifically with a nuclear protein since the other panel of 4ET/HA 
double staining displayed only 4ET/HA positive cytoplasmic puncta (contrast Figure 2.2B 
with Figure 2.2A). 
 
Given that HA-tagged 4E-T is overexpressed in Y30A and 4ET at the mRNA and protein 
level and is represented by cytoplasmic puncta (Figures 2.2-2.3), the data strongly suggest 
that I have established a robust 4E-T overexpression cell lines. 
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Table 2.1.  Antibody concentrations used for indirect immunofluorescence. 
Figure Primary antibody primary 
antibody 
dilution 
Secondary antibody* secondary 
antibody 
dilution 
4ET single stain 
(Figure 2.2A) 
4ET (mouse; 
Abnova H00056478-
B01) 
1:100 Texas red 
conjugated goat anti-
mouse  
1:100 
HA single stain 
(Figure 2.2B) 
HA (mouse; Santa 
Cruz F7 SC-7392 
1:100 Texas red 
conjugated goat anti-
mouse  
1:100 
4ET/HA double 
stain (Figure 2.3A)  
4ET (mouse; 
Abnova H00056478-
B01); HA (rabbit; 
Santa Cruz Y-11 SC-
805) 
1:100; 
1:100 
Texas red 
conjugated goat anti-
mouse; Cy5 
conjugated donkey 
anti-rabbit  
1:100; 
1:100 
4ET/HA double 
stain (Figure 2.3B) 
4ET (rabbit; Abcam 
ab55881); HA 
(mouse; Santa Cruz 
F7 SC-7392) 
1:100; 
1:100 
Texas red 
conjugated goat anti-
rabbit; Cy5 
conjugated donkey 
anti-mouse antibody 
1:100; 
1:100 
*all are from Jackson Immunoresearch
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 Table 2.2.  Flow cytometry data from BD FACSAria sorted pMSCV-infected U2Os cells. 
Sample Percentage GFP positive Number of cells sorted 
U2Os pMSCVY30A 55.4% 1 506 450 
U2Os pMSCV4ET 86.6% 1 442 280 
U2Os pMSCVE 99.6% 1 126 263 
 
 
 
 
Figure 2.1.  4ET is overexpressed in Y30A and 4ET cell lines as compared to the E control.  
A) Western blot against 4E-T and HA, tubulin (Tub) shown as a loading control.  B) RT-
qPCR for 4E-T mRNA normalized by actin and relative to E control. 
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Figure 2.2  Indirect immunofluorescence in the cell lines.   
A)  HA signal (red) is observed as cytoplasmic puncta in Y30A and 4ET but not E; B) 4ET 
signal (red) is observed as a cytoplasmic puncta in Y30A and 4ET and as more diffuse 
staining throughout the cell in E.  DAPI (cyan) marks DNA in nuclei, PC (phase contrast). 
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Figure 2.3.  Micrographs demonstrating that overexpressed 4E-T is also HA-tagged. A) 
4ET FL mouse antibody and rabbit HA; B) Abcam 4ET rabbit antibody and mouse HA. 
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Chapter 3. Overexpression of 4E-T causes the formation 
of processing bodies 
Introduction 
 
4E-T is a component of cytoplasmic foci known as processing bodies (P-bodies) 
(Ferraiuolo, et al., 2005).  P-bodies are ribonucleotide complexes composed of several 
proteins (refer to Table 1.6) whose function within cells was discussed in Chapter 1. 
 
Given that overexpression of 4E-T results in cytoplasmic puncta, it is important to 
determine whether these entities are P-bodies.  Decapping protein 1 a (Dcp1a) is a well-
established component of P-bodies which are not found in SGs (Cougot, Babajko, & 
Seraphin, 2004; Kedersha, et al., 2005).  Therefore, co-localization of 4E-T and Dcp1a in 
the cytoplasmic puncta in the 4ET cell line (by immunofluorescence) would support the 
notion that 4E-T overexpression induces the formation of (large) P-bodies.   
 
Another method to test the formation of P-bodies in the 4ET overexpression cell line is to 
demonstrate their disappearance (by immunofluorescence) upon treatment with a P-body 
dispersion drug.  Emetine is a drug that can disassemble both P-bodies and stress granules 
(reviewed in (Kedersha & Anderson, 2007). 
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Materials and Methods 
 
4E-T overexpression cell lines 
U2Os cells overexpressing 4E-T and the mutant non-4E-binding form of 4E-T as well 
vector control were described in Chapter 2. 
 
Emetine treatment 
20 µg/ml emetine (Sigma) was applied to cells grown on coverslips for 1 hour, 1.5 hours, 
and 2 hours (37 oC) prior to fixation and immunofluorescence staining.  Untreated controls 
of all cell lines was also collected. 
 
Indirect Immunofluorescence 
The indirect immunofluorescence procedure was as described in Chapter 2.  Rabbit anti-
Dcp1a serum was used to identify Dcp1a-positive entities (gift from Andersen lab; 1:100 
dilution).   
 
Results 
 
4E-T overexpression leads to the formation of P-bodies 
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The Y30A and 4E-T overexpression lines both demonstrate the ability of 4E-T to 
colocalize Dcp1a in the cytoplasm (Figure 3.1) suggesting that it does not have to bind 4E 
in order to be part of P-bodies.  Since Dcp1a is a marker for P-bodies, it is surmized that the 
4E-T-positivie/Dcp1a-positive cytoplasmic puncta seen in Y30A and 4E-T are P-bodies.  
The vector control (E) does not show large Dcp1a positive cytoplasmic puncta (contrast E 
with Y30A and 4E-T in Figure 3.1).  By Western blot, there does not seem to be a gross 
increase in the level of Dcp1a protein in Y30A and 4ET as compared to E (Figure 3.2). 
 
Emetine treatment causes the disappearance of P-bodies 
The Y30A cell line displayed more diffuse 4ET and Dcp1a staining with emetine treatment 
starting at 1 hour with almost complete disappearance of 4ET/Dcp1a positive cytoplasmic 
bodies by 2 hours of emetine treatment as compared to the untreated control (Figure 3.3).   
 
The 4ET cell line showed 4ET bodies that resisted dispersal with emetine treatment.  
However, these bodies appeared to become smaller and surrounded by more diffuse 4ET 
staining with increasing incubation time with emetine as compared to the untreated control 
(Figure 3.4).   The Dcp1a staining was completely colocalized with 4ET staining in the 
untreated control and was observed as cytoplasmic puncta surrounded by more diffuse 
Dcp1a staining with increasing incubation time with emetine (Figure 3.4).  After 2 hours of 
emetine treatment the Dcp1a signal was no longer colocalized with 4ET signal (contrast 
bottom panel of Figure 3.4 with top panel of Figure 3.4). 
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Discussion 
Given that both the Y30A and 4ET cell lines were able to produce cytoplasmic puncta that 
were positive for 4ET and Dcp1a (Figures 3.1, 3.3 and 3.4) which were not observed in the 
vector control line E, the data suggest that overexpression of 4ET (whether the wild type 
form or less effectively-4E binding form) do induce the formation of P-bodies.  These data 
are consistent with data presented by Ferraiuolo et al., 2005 who suggest that localization of 
4ET to P-bodies does not require interaction with 4E.  The dissolution of 4ET bodies with 
increasing incubation times with emetine in the Y30A cell line also supports the notion that 
P-bodies were present in this cell line.  The overexpression of 4ET does not appear to affect 
the protein levels of Dcp1a  as seen by Western blot (Figure 3.2). 
 
The persistence of 4ET bodies in the 4ET cell line may be a function of the level of 4ET 
overexpression in this cell line as compared to either Y30A or E (see Chapter 2 Figure 2.1).  
However, the dissociation of Dcp1a from 4ET at 2 hours of emetine treatment and the more 
diffuse 4ET staining around the 4ET puncta present with emetine treatment suggest that the 
P-body dissassembly drug was able to partially dissociate P-bodies seen in the 4ET line.   
 
A similar study of overexpression of another P-body protein (Pat1b)  by Ozgur et al. (2010) 
suggest an alternate explanation for resistance to diassembly in the presence of another 
translation elongation inhibitor (cyclohexamide).  When Pat1b protein was overexpressed, 
the induced P-bodies resisted disassembly in the presence of cyclohexamide (even after 6 
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hours of treatment) which they interpreted as meaning that Pat1b plays a role in stabilizing 
P-bodies ((Ozgur, Chekulaeva, & Stoecklin, 2010).  Therefore, 4ET could also be 
important for the stability of P-bodies.   When 4ET was depleted in a cell line with 
endogenously high levels of 4E and P-bodies (FaDu cell line), P-bodies disappeared which 
also suggests that 4ET is important for stability of P-bodies (Supplemental Figure S.1). 
 
Small 4ET/Dcp1a positive bodies are seen in the untreated E line.  In the presence of 
emetine, E shows only diffuse staining of both 4ET and Dcp1a (Figure 3.5).   
 
As emetine is a drug that blocks protein synthesis in eukaryotic cells by binding to the 40S 
subunit of the ribosome (Jimenez, Carrasco, & Vazquez, 1977), it is unlikely to itself 
directly cause the degradation of Dcp1a or 4ET protein.  However, in order to demonstrate 
that emetine treatment was affecting only the localization of Dcp1a and 4ET, one would 
have to repeat the experiment and perform Western blot analysis for Dcp1a and 4ET.  
Given that Ferraiuolo et al., 2005 demonstrated that Dcp1a or 4ET protein levels were 
unchanged in Hela cells when subjected to 0, 30 and 60 minutes of cyclohexamide, it is 
expected that emetine treatment will have similar effects.  
 
Together, the data strongly suggest that overexpression of both the mutant and wild type 
forms of 4ET induce the formation of P-bodies but that those P-bodies formed in the 4ET 
cell line are more resistant to disassembly with emetine treatment. It is suggested that the 
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inability to completely dissassemble P-bodies in the 4ET cell line could be overcome with 
either increased incubation time and/or increased concentration with emetine.    
 
Treating Y30A, 4ET, and E cell lines with another P-body disassembly drug such as 
cyclohexamide (1- 2 hour treatment with 20-50 ug/ml as suggested in (Kedersha & 
Anderson, 2007); and as observed in yeast in (Brengues, et al., 2005) might also be 
performed to lend further credence to the notion that the cytoplasmic 4ET/Dcp1a positive 
bodies seen in Y30A and 4ET are indeed P-bodies.  
 
As P-bodies contain a large number of protein components (refer to Table 1.6 in Chapter 
1), it is also possible (albeit exhaustive) to test for the colocalization of other P-body 
components with 4ET by immunofluorescence. 
 
The presence of P-bodies changes with the cell cycle.  Therefore, increasing the size and/or 
number and/or half-life of P-bodies could have an effect on the cell cycle.  In fact, a recent 
study showed that overexpression of a splice variant of the tumor supressor gene TFL 
(transformed follicular lymphoma, P58TFL) resulted in the formation of P-bodies and an 
inhibition of G1 to S phase progression (Minagawa et al., 2009).   Cell synchronization 
experiments (e.g. double thymidine block) combined with BrDU analysis to address cell-
cycle associated changes in 4ET and/or P-bodies could be of benefit to address these issues.  
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I suspect that cell cycle has not drastically been altered in Y30A and 4ET as compared to E 
as all cell lines did not display growth defects (Wu unpublished observation). 
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Figure 3.1.  Micrographs showing subcellular localization of 4E-T and Dcp1a. 
 
 
 
 
 
 
 
 
Figure 3.2.Western blot of Dcp1a. 
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Figure 3.3.  Micrographs of Y30A cell line showing disappearance of P-bodies with 
increasing emetine treatment. 
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Figure 3.4.  Micrographs of 4ET cell line showing disappearance of P-bodies with 
increasing emetine treatment. 
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Figure 3.5.  Micrographs of E cell line untreated, and treated with emetine for 1 hour, 1.5 
hours, and 2 hours. 
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Chapter 4.  4E-T overexpression relocalizes a proportion 
of 4E in U2Os cells. 
Introduction 
Having established cell lines that overexpress 4E-T (wild type overexpression line will 
heretofore be referred to as 4ET or 4ET line and the mutant overexpression line will be 
referred to as Y30A or Y30A line) and induce the formation of P-bodies (see Chapters 2 
and 3), it is important to investigate the impact of these changes on the cellular levels 
(mRNA and protein) and subcellular localization of 4E.  If the overexpression of 4E-T is 
able to relocalize a proportion of 4E to P-bodies, then it has the potential of altering the 
function of 4E. 
  
Materials and Methods 
 
4E-T overexpression cell lines 
U2Os cells overexpressing 4E-T and the mutant non-4E-binding form of 4E-T as well 
vector control were described in Chapter 1. 
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Indirect Immunofluorescence 
The indirect immunofluorescence procedure was as described in Chapter 2.  In order to 
demonstrate co-localization of 4E-T with 4E, a rabbit 4E-T antibody was used (1:100 
dilution; Abcam ab55881)  
 
Western blot 
Western blot was conducted as described in Chapter 2.   
 
RNA collection 
RNA collection was as described in Chapter 2. 
 
RT-PCR and qPCR 
RT-PCR and qPCR were performed as described in Chapter 2.  4E forward primer 5’ 
CTGTGCCTTATTGGAGAAT 3’ and reverse primer 5’ 
GGAGGAAGTCCTAACCTTT3’. 
 
Results 
 
4E-T overexpression can relocalize endogenous 4E 
Overexpression of the wild type form of 4E-T (4ET) as well as the mutant form of 4E-T 
(Y30A) can relocalize 4E to the cytoplasm. (Figure 4.1A).  In the vector control (E), 4E is 
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observed to have less cytoplasmic staining as compared to either 4ET or Y30A (Figure 
4.1A).  The 4E-T-positive foci in the 4ET overexpression cell line more effectively 
colocalize 4E than Y30A (Figure 4.1B). 
 
Overexpression of 4E-T does not alter the protein level or mRNA level of 4E 
The protein level of 4E does not appreciably differ between Y30A and 4ET and E (Figure 
4.2A).  By RT-qPCR, 4E mRNA levels are very slightly reduced in 4ET and slightly 
elevated in Y30A relative to E (Figure 4.2B).  However, these slight variations in 4E 
mRNA had no impact on 4E protein level. 
 
Discussion 
 
Although overexpression of both the mutant and wild type forms of 4E-T are able to 
relocalize 4E as compared to the vector control (E) (compare 4E staining of E to Y30A and 
4ET in Figure 4.1A), the overlap in indirect immunoflourescence signals is more complete 
in 4ET as compared to Y30A (compare circled regions highlighted in Figure 4.1B).  The 
mutation in Y30A has been demonstrated to inhibit 4E binding by immunoprecipitation 
(Dostie et al., 2000).  However, as the Y30A cell line was able to relocalize some 4E as 
compared to E (Figure 4.1A and 4.1B), it is possible that the single amino acid mutation 
may not be sufficient to completely abrogate the 4E-T-4E interaction.  Since the consensus 
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sequence for 4E binding partners is YXXXXL", perhaps a 4E-T mutant containing a Y to 
A as well as L to A would be a better mutant. 
 
It is also possible that 4ET has different affinities for the different classes of 4E family 
members (refer to Table 1.1 in Chapter 1).  As our 4E antibody is unlikely to be able to 
distinguish between the different classes of 4E, it impossible to determine the specificity of 
Y30A or 4ET for the various classes of 4E either by Western blot or by 
immunofluorescence at this time.   
 
It would appear that the mRNA levels and protein abundance of 4E is not significantly 
different between Y30A and 4ET as compared to E (see Figure 4.2).  If anything, the 
mRNA level of 4E is slightly reduced in 4ET and slightly elevated in Y30A as compared to 
E while the protein levels (by visual inspection) would appear to approximately the same in 
all cell lines.  To more accurately describe the protein levels of 4E in the cell lines, one 
would need to use densitometry and quantification software.   
 
Together, these data suggest that the 4ET line is more effective at producing P-bodies that 
relocalize a proportion of 4E as compare to Y30A without greatly affecting the total level 
of 4E mRNA or protein levels.   
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Figure  4.1. Overexpression of 4E-T relocalizes endogenous 4E.  A)  Both Y30A and 4ET 
(red) can relocalize 4E (green) more than E.  B) 4ET forms more distinct 4E-positive 
cytoplasmic foci than Y30A.  Pink circles are shown around representative 4E-T foci for 
4ET and Y30A 
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Figure  4.2.  4E-T overexpression does not drastically alter the protein level or mRNA level 
of 4E.  A) Western blot of 4E in Y30A, 4ET, and E; actin shown as a loading control; B) 
RT-qPCR data for 4E (delta delta Ct as a function of cell line) for Y30A, 4ET, and E.  
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Chapter 5.  Impact of 4E-T overexpression on 4E-SE-
containing transcripts and the protein products of 4E-
sensitive transcripts. 
Introduction 
 
To this point, I have demonstrated that the 4ET line induces the formation of P-bodies that 
can more effectively relocalize a proportion of 4E protein without altering 4E 
mRNA/protein levels than the Y30A line (Chapters 3 and 4). In this chapter I investigate 
the potential impact of 4ET overexpression on 4E function.  More specifically, I address the 
impact of 4ET overexpression on the expression and cytoplasmic to nuclear distribution of 
4E-SE-containig transcripts (cyclin D1, Pim1, nibrin, CGGbp, and NONO.1), a 
translationally sensitive transcripts (VEGF), and 4E sensitive transcripts containing 4E-SE 
(Pim1 and ODC) by using cellular fractionation and RT-qPCR. 
 
Materials and Methods 
4E-T overexpression cell lines 
U2Os cells overexpressing 4E-T and the mutant non-4E-binding form of 4E-T as well 
vector control were described in Chapter 2. 
 
Western blot 
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Western blot was conducted as described in Chapter 2.  Only total protein lysates were 
analyzed.  Targets tested are summarized in Table 5.1. 
 
RNA collection 
RNA collection was as described in Chapter 2. 
 
Cellular fractionation 
Cells were grown to near confluence (approximately 3 X 107 cells), rinsed 2X with cold 
PBS and collected by trypsinization.  Cell pellets were gently resuspended in ice cold Lysis 
B solution (10 mM Tris pH 8.4, 140 mM NaCl, 1.5 mM MgCl2, 0.5% NP40, 1 mM DTT 
and 200 U/ml RNAseOut (Invitrogen)).   Cell suspensions were centrifuged at 1000 X g at 
4oC for 3 minutes.  Supernatant (cytoplasmic fraction) was resuspended in 1 ml Trizol 
(Invitrogen) and RNA extraction was performed as described in Chapter 1.  The pellet 
(nuclear fraction) was resuspended in 1 ml Lysis B solution, transferred to a round bottom 
polypropylene tube and 100 µl of detergent stock (3.3% w/v sodium deoxycholate, 6.6% 
v/v Tween 40 in DEPC dH2O) was added under slow vortexing, and then incubated for 5 
minutes on ice.  Nuclear suspensions were transferred to 1.5 ml eppendorf tubes and 
centrifuged at 1000 X g at 4oC for 3 minutes.  Supernatant was discarded, pellets 
resuspended in 1 ml Lysis buffer B and recentrifuged at 1000 X g at 4oC for 3 minutes. 
Supernatant was discarded and cell pellets (nuclear fractions) were resupsended in 1 ml 
Trizol and RNA extraction was performed as described in Chapter 1. 
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RT-PCR and qPCR 
RT-PCR and qPCR were performed as described in Chapter 1.  U6 primers were used to 
confirm that nuclear fractions were enriched for U6 transcripts (Forward 5’ 
CGCTTCGGCAGCACATATAC 3’; Reverse 5’ AAAATATGGAACGCTTCACGA 3’).  
Primers for tRNALys were used to show that cytoplasmic fractions were enriched for 
cytoplasmic fractions (forward 5’ GCCCGGATAGCTCAGTCGGT 3’; reverse 5’ 
CGCCCAACGTGGGGCTCTCG 3’). 
 
Various 4E target genes (4E-SE and/or 4E-sensitive) were analyzed by RT-qPCR (Table 
5.1).  All qPCR data is reported relative to E and normalized to tubulin.  Delta delta Ct 
values in the range of 0.33 to 3.00 are arbitrarily determined to be equivalent (e.g. not 
differing from E) such that values of less than 0.33 (e.g. 3-fold reduced) are described 
reduced and greater than 3.00 (e.g. 3-fold enriched) are described as 3-fold enriched. 
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Table 5.1. Western blot targets. 
Category and gene Company Dilution 
4E-SE : 
CyclinD1 
Cyclin E1 
Mdm2 
 
(H-295) sc-753 Santa Cruz 
(C-19) sc-198 Santa Cruz 
(Ab-1) OP46-100 ug Oncogene 
 
1 :500 
1 :200 
1 :500 
4E-sensitive : 
VEGF 
 
(A-20) sc-152 Santa Cruz 
 
1 :500 
Normalization : 
actin 
 
A54411 Sigma 
 
1 :5000 
 
 
 
 
 
 
 
 
 
Table 5.2. Primers and targets for RT-qPCR 
Category and gene Forward primer Reverse primer 
4E-SE : 
NONO.1 
Nibrin 
CycD1 
 
AGGTCCTTCCTGCTAACCACATT 
AGCAGCAGACCAACTCCATCAGAA 
CAGCGAGCAGCAGAGTCCGC 
 
TCATACTCAAACCCAGCCAGGCTGT 
TCCACAATGAGGGTGTAGCAGGTT 
ACAGGAGCTGGTGTTCCATGGC 
4E-SE and 4E-
sensitive : 
Pim1 
 
 
ACACCTTGGGATGGGATAGGA 
 
 
GAGAAGCAGCACCTAAAAGAGGC 
4E-sensitive : 
VEGF 
 
TGCCAAGTGGTCCCAGGCTG 
 
CGGCTTGAAGATGTACTCTAT 
Normalization : 
Tubulin 
 
AGCATCCAGTTTGTGGATTGGTGC 
 
CAAAGGCACGCTTGGCATACATCA 
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Results 
Confirmation of cellular fractionation 
OneStep PCR was performed for tRNAlys to confirm that cytoplasmic fractions were 
enriched for tRNAlys RNA (Figure 5.1A).  U6 snRNA RT-qPCR was performed to 
confirm the quality of the nuclear fractions (Figure 5.1B). Fractionation was efficient for all 
of the cell lines as seen by nuclear enrichment for U6 and cytoplasmic enrichment for 
tRNAlys. 
 
Total levels of 4E-SE, 4E-sensitive, and 4E-SE containing 4E sensitive transcripts 
The total levels of mRNA for 4E-SE transcripts (NONO.1, Nibrin, CycD1, and CGGbp1), 
4E-sensitive transcripts (VEGF), and 4E-SE containing 4E-sensitive transcripts (Pim1 and 
ODC) do not differ between Y30A, 4ET and E (Figure 5.2A, C, E and G, and Figure 5.3A, 
C, and E). 
 
4ET line has cytoplasmic enrichment of certain transcripts 
Relative to E, 4ET shows a cytoplasmic enrichment for the 4E-SE containing transcripts 
cyclin D1 and the 4E-SE containing 4E-sensitive transcript ODC. (Figure 5.2D, and 5.3F). 
 
Y30A line has nuclear enrichment of certain transcripts 
Relative to E, Y30A has a nuclear enrichment for the 4E-SE transcripts cyclin D1 (Figure 
5.2D). 
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Y30A and/or 4ET show no difference in cytoplasmic or nuclear enrichment for certain 
transcripts 
Both Y30A and 4ET show no difference relative to E for cytoplasmic or nuclear 
enrichment for 4E-SE containing transcripts NONO.1, nibrin, and CGGbp (Figure 5.2B, F, 
and H); VEGF (4E-sensitive transcript; Figure 5.3B), or Pim1 (4E-SE containing 4E-
sensitive transcript) (Figure 5.3D).   
 
Pim1 (4E-SE containing 4E-sensitive transcript) and CycD1 (4E-SE transcript) are not 
different with respect to their cytoplasmic/nuclear distribution for Y30A as compared to E 
(Figures 5.3D, and 5.2D). 
 
Western blot data 
Cyclin D1 and Mdm2 protein levels are enriched in Y30A and 4ET relative to E (Figure 
5.4).  Cyclin E1 and VEGF protein levels were similar in Y30A, 4ET, and E cell lines 
(Figure 5.4). 
 
Discussion 
 
4ET overexpression does not affect transcription of the examined targets  
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Anecdotal data suggests that 4ET may be present at the promoter of the transcription factor 
SCL (Hoang lab, unpublished).  Therefore, if 4ET were to promote the transcription of 
SCL, when 4ET is overexpressed, transcriptional targets of SCL could also be elevated.  
However, since the total level of mRNA for all targets tested (NONO.1, cyclin D1, Nibrin, 
CGGbp, VEGF, and Pim1 (Figures 5.2 and 5.3) was unchanged between Y30A, 4ET, and 
E, either these transcripts are not SCL transcriptional targets or the overexpressed 4ET does 
not have transcriptional activation activity. Overexpression of a tagged version of 4ET 
(such as the HA-tagged version of 4ET presented in the present study) in a cell line that has 
endogenously high levels of SCL followed by chromatin immunoprecipitation (ChIP) 
against HA could be performed to confirm the presence of 4ET at the SCL promoter.  RT-
qPCR for SCL and/or SCL transcriptional targets in Y30A, 4ET, and E would further 
resolve whether 4ET has a link to SCL.  
 
Nevertheless, the total amount of the transcripts tested did not vary upon 4ET 
overexpression. 
 
4ET overexpression can sequester certain transcripts in the cytoplasm 
Although 4ET overexpression does not alter total levels of the 4E targets tested, it does 
appear to have an effect on the cytoplasmic and nuclear distribution of some of the targets.   
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Since there is an enrichment in the cytoplasm for cyclin D1 and ODC when 4ET is 
overexpressed (Figures 5.2D, and Figure 5.3F), it is possible that 4ET with 4E is 
sequestering these transcripts in the cytoplasm, presumably in P-bodies. To confirm the 
presence of cyclin D1 and ODC transcripts in P-bodies, one could perform fluorescence in 
situ hybridization against these transcripts combined with immunofluorescence against 4ET 
and 4E.  Since the cytoplasmic enrichment of these targets is not seen in the Y30A line (and 
is more enriched in the nuclear fraction in the case of cyclin D1), the cytoplasmic mRNA 
sequestration (without degradation) may be dependent on a strong interaction of 4ET with 
4E. Alternatively, the Y to A mutation of Y30A may abrogate the 4ET-mRNA or 4ET-
RNA binding protein X-mRNA complex that stabilizes the cytoplasmic accumulation of 
cyclin D1 and ODC transcripts.   
 
Possible mechanisms for 4ET interaction with  cyclin D1 and ODC transcripts 
Since there was no difference in cytoplasmic/nuclear distribution for all other 4E-SE 
containing transcripts tested, the effect of 4ET overexpression is not universal for all 4E-SE 
containing transcripts.   
 
The apparent cytoplasmic sequestration of certain transcripts in the 4ET line may be a 
consequence of P-body formation without a concomitant increase in P-body proteins 
involved in mRNA degradation.  As seen in the case of overexpression of other P-body 
proteins (tristetraprolin (TTP) and BRF-1), the overexpression of 4ET may nucleate 
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submicroscopic P-body subcomplexes that contain certain mRNA ((Franks & Lykke-
Andersen, 2007).  Franks and Lykke-Andersen (2007) suggest that these subcomplexes 
aggregate to become microscopically visible because there are not enough mRNA 
degradation enzymes to degrade the accumulated mRNA.  This hypothesis is supported by 
Western blot data for the degradation enzyme Dcp1a presented earlier (Figure 3.2), where 
no gross changes in its protein level were observed in Y30A and 4ET as compared to E.  
Since the mRNA decay enzymes are limiting, I posit that the mRNAs found within the P-
bodies (perhaps cyclin D1 and ODC) accumulate in the cytoplasm rather than degrade.  As 
the level of 4ET overexpression in the 4ET is so much greater than 4ET in Y30A, (compare 
4ET level in 4ET line to Y30A line in Figures 2.1A) cyclin D1 and ODC transcripts 
aggregate in P-bodies rather than degrade.  Thus, the stability of these particular transcripts 
in the cytoplasm may be increased.  Additional experiments exploring differences in 
stability of transcripts in cytoplasmic and nuclear compartments (e.g. using actinomycin D) 
could be performed to address this possibility. 
 
Possible mechanisms for 4ET interaction with cyclin D1 and ODC transcripts 
4ET protein could interact directly with an mRNA element common to cyclin D1 and 
ODC. To help identify the mRNA element could be a common sequence or secondary 
structure recognized by the 4ET protein, one could perform bioinformatic analysis of cyclin 
D1 and ODC transcripts. In order to provide more data to support the notion that cyclin D1 
and ODC transcripts are associated with 4ET in P-bodies, one could perform RNA 
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immunoprecipitation (RNAIP).  As I have created HA-tagged cell lines that overexpress 
4ET, it is possible to perform and RNA-IP against HA followed by RT-PCR for cyclinD1 
and ODC. A possible protocol for isolation of ribonculeoprotein immunoprecipitation 
(RNP-IP) is presented by (Hassan et al., 2010).  The mRNA element is unlikely to be the 
AU-rich element (ARE) or the cytoplasmic polyadenylation element (CPE) since these 
elements are not unique to cyclin D1 and ODC (Table 5.3).  
 
4ET could interact with cyclin D1 and ODC transcripts via its interaction with another 
protein.  Clues to the nature of the relationship between 4ET and certain mRNAs may be 
gained from studies of 4ET paralogues in other species.  In Xenopus, eIF4E1b and eIF4E 
interact with 4E-T (Standart & Minshall, 2008).  When complexed with eIF4E1b, the 
Xenopus 4E-T interacts with cytoplasmic polyadenylation element-binding protein (CPEB), 
that in turn interacts with cytoplasmic polyadenylation elements of certain mRNAs such as 
cyclin (Standart & Minshall, 2008).  The interaction between eIF4E1b and Xenopus 4ET is 
independent of the YXXXXL" site, suggesting a separate interaction site than that of 
eIF4E.  In my system, it is impossible to determine if the 4E protein that interacts with 
overexpressed 4ET is eIF4E or eIF4E1b since our antibody is unable to distinguish between 
these proteins.   
 
Possibility of identifying additional mRNAs in 4ET-induced P-bodies 
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Studies by Kedersha et al. (2005) suggest that a single class of mRNA localizes to both SGs 
and P-bodies.  However, as these studies used a MS2-reporter construct, they did not 
identify endogenous mRNA targets (Kedersha, et al., 2005).  AU-rich element (ARE) 
mRNAs have been observed in P-bodies (Franks & Lykke-Andersen, 2007).  Another P-
body component, GW182, contains an RNA recognition motif (aa 1528-1600) to which a 
number of mRNA targets were found to bind (Eystathioy et al., 2002).  However, cyclin D1 
and ODC were not identified in their study as being more than 2-fold enriched. Eystathioy 
et. al (2002) employed a 1200 cDNA array, therefore, they were unlikely to identify all 
possible mRNAs found within P-bodies.  Cyclin D1, ODC, Pim1, and VEGF were included 
on their array but NONO.1, nibrin, and CGGbp were not.   
 
Again, as I have created an HA-tagged 4ET overexpression cell line, it would be possible to 
perform HA-RNAIP, recover the RNA and perform deep sequencing to identify target 
transcripts.  Since P-bodies are transient structures whose components may also be in flux, 
it may prove difficult to isolate enough material to perform such an experiment (Leung & 
Sharp, 2006).  Other challenges in P-body isolation could arise due to their molecular mass, 
low abundance and/or incompletely understood physicochemical properties (e.g. high-
density hydrophobic proteins such as GW182).  Special precautions should be considered 
in the IP such as modified protocols described by (Moser, Chan, & Fritzler, 2009) and 
(Hassan, et al., 2010).  
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As suggested by Standart and Minshall (2008), the specific inhibition of translation of 
target mRNAs could be renewed by altering 3’ UTR RNP dynamics—another mechanism 
adding to the complexity of the mRNA regulon. 
 
4ET overexpression probably has no effect on the translation ability of 4E 
Since 4ET overexpression was shown to relocalize a proportion of endogenous 4E protein 
to P-bodies, it was hypothesized that this pool of 4E would be unavailable to be assembled 
into translation initiation machinery.  Therefore, translation, particularly of 4E-sensitive 
targets, should be impeded.  However, no decrease in protein was observed for VEGF (4E-
sensitive transcript) (Figure 5.4).  I failed in my attempts to perform Western blots for ODC 
and Pim1 (other 4E-sensitive transcripts that also contain a 4E-SE).   
 
Since Cyclin E1 (a 4E-SE containing transcript that is not 4E-sensitive) and actin (non 4E-
SE containing and non 4E-sensitive) were unchanged in Y30A, 4ET, and E, 4ET 
overexpression had no effect on the translation of these transcripts.   
 
The observation that cyclin D1 and Mdm2 proteins were elevated in Y30A and 4ET as 
compared to E was unexpected (Figure 5.4).  Elevated cyclin D1 protein in the 4ET line 
could be a consequence of the cytoplasmic enrichment for this transcript (Figure 5.2D).  
Paradoxically, Y30A shows an elevated level of cyclin D1 protein despite having a nuclear 
enrichment of cyclin D1 transcript (Figures 5.4 and 5.2D). Perhaps the loading of 
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ribosomes onto cyclin D1 and Mdm2 transcripts in Y30A and 4ET was more efficient than 
in E (to be assessed by polysome analysis), or the cyclin D1 and Mdm2 proteins are 
somehow made more stable in Y30A and 4ET as compared to E.   HA-IP followed by 
Western blot for cyclin D1 and Mdm2 would be an experiment to test the protein-protein 
interaction hypothesis. 
 
Possible reasons for 4ET overexpression not interfering with 4E function 
Although overexpression of 4E-T may relocalize and/or concentrate 4E into cytoplasmic 
puncta (presumed to be P-bodies; see Chapters 2 and 3), it may not be sufficient to interfere 
with 4E’s cytoplasmic functions.  Since P-bodies involve more than 20 proteins (see Table 
1.6), the co-expression of one or more other P-body components may be required to more 
efficiently shift the equilibrium of 4E cytoplasmic localization and function (e.g. to be more 
involved in P-bodies and less involved with mRNA translation initiation).  Perhaps the 
overexpression of P-body proteins that are known to interact with mRNAs slated for decay 
in P-bodies (e.g. TTP, BRF, Dcp1a, Dcp1b, Dcp2, Ccr4, Lsm, rck/p54 (Cougot, et al., 
2004; Franks & Lykke-Andersen, 2007) need to be co-overexpressed with 4ET process to 
induce a P-body mediated change in the oncogenic potential of 4E. 
 
It is possible that post-translational modifications of 4ET are required for it to relocalize 4E 
more efficiently to P-bodies.  Following this logic, despite 4ET being overexpressed, the 
molecular pathways that are responsible for the addition/removal of post-translational 
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modifications that enhance 4ET-4E interaction may not be activated sufficiently to 
radically change that subcellular localization of 4E to P-bodies.  Given that 4ET has several 
phosphorylation sites (refer Figure 1.1 in Chapter 1) and that its phosphorylation status 
changes in the cell cycle (Pyronnet & Sonenberg, 2001), it is possible that 
phosphorylation/dephosphorylation is one such post-translational modification.  Therefore, 
overexpression in different cell lines may yield different effects on 4E-SE transcripts and/or 
translationally sensitive transcripts. 
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Figure 5.1.  Fractionation controls.  A) OneStep PCR of the cytoplasmic control tRNAlys; 
B) RT-qPCR for nuclear control U6.  
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Figure 5.2.  RT-qPCR results for 4E-SE transcripts. A, C, E, and G represent total RNA.  B, 
D, F, and H represent cytoplasmic/nuclear (C/N) transcripts. A and B) NONO.1; C and D) 
Cyclin D1; E and F) Nibrin; G and H) CGGbp; * denotes enriched in cytoplasmic fraction; 
** denotes enriched in nuclear fraction. 
A. B. 
C. D. 
E. F
. 
G. H. 
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Figure 5.3.  RT-qPCR results for 4E-sensitive and 4E-SE containing 4E-sensitive 
transcripts.  A, C, and E represent total RNA; B, D, and F represent C/N RNA.  A and B) 
VEGF (4E-sensitive); C and D) Pim1 (4E-SE containing 4E-sensitive) E and F) ODC (4E-
SE containing 4E-sensitive) ; * denotes enriched in cytoplasmic fraction.  
A. B. 
C. D. 
E. F. 
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Figure 5.4. Western blot results for products of 4E-sensitive and 4E-SE containing 
transcripts.  
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Table 5.3.  RNA elements in transcripts tested. 
Gene Cytoplasmic 
enrichment of 
RNA? 
Elevated 
total 
protein? 
translation
-sensitive? 
4E-SE IRES1 ARE2 CPEB3 
Cyclin D1 Yes Yes No Yes No Yes Yes 
ODC Yes ? Yes Yes Yes No Yes 
NONO.1 No ? ? Yes No No Yes 
Mdm2 ? Yes No Yes No No Yes 
CGGbp No ? ? Yes No Yes Yes 
VEGF No No Yes No Yes Yes Yes 
Pim1 No ? Yes Yes Yes Yes Yes 
Nibrin No ? ? Yes No No Yes 
Cyclin E1 ? No ? Yes No No Yes 
1 results from database http://iresite.org;  
2 results from database http://rc.kfshrc.edu.sa/bssc/ARED_GENE;  
3 results from search for TTTTTAT, TTTTTG, TTTTTACU, TTTTAAT, TTTTACT, 
TTTTATT  
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Chapter 6.  4E-T overexpression effect on polysome 
profile. 
Introduction 
Having established that the 4ET and Y30A lines induce the formation of P-bodies (Chapter 
2), I wanted to investigate the impact of P-body formation on polysome profile and the 
distribution of 4E-SE-containing, and 4E-sensitive transcripts on polysomes.   
 
I reasoned that the induction of P-bodies could affect polysome profile because of the 
observation of an inverse relationship between translation and P-bodies (Teixeira, et al., 
2005) and an apparent reciprocal relationship between polysomes and P-bodies (see 
(Brengues, et al., 2005).   
 
Since 4E protein plays a role in the assembly of ribosomes to cap-bearing transcripts and it 
was observed that some 4E is relocalized to cytoplasmic puncta with 4ET overexpression 
(Chapter 4), I also wanted to investigate the distribution of 4E-SE-containing transcripts 
and 4E-sensitive transcripts. 
 
Due to time constraints, I restrict my analyses to the 4ET and E cell lines.  Fractions were 
collected for the Y30A line at the same time as data presented here.  The Y30A data may 
be used at a later date. 
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Materials and Methods 
Cell lines 
Overexpression cell lines were those generated and described in Chapter 2 (4ET and E). 
 
Polysome profile generation 
Each cell line was seeded at (1 X 106 cells/plate) X4 and grown for 3 days at 37oC 5% CO2.  
Cells were treated with cyclohexamide (100 µg/ml) for 15 minutes at 37oC, washed with 
PBS + cyclohexamide (100 µg/ml), scraped, centrifuged (800 X g, 5 minutes), and 
resuspended in 600 µl LSB (50 mM Tris pH 7.5, 250 mM KCl, 5 mM MgCl2, 1mM DTT, 
400 U/ml RNAseOUT, 100 ug/ml cyclohexamide and 1% TritonX100).  Resuspensions 
were kept on ice for 30 minutes with occasional vortexing and then centrifuged at 3000 X g 
for 10 minutes at 4oC.  Supernatant was centrifuged at 12000 X g. for 10 minutes at 4oC.  
100 µl of this supernatant (ribosome preparation) was reserved for input RNA and 4 µl was 
resuspended in 400 µl H20 to measure absorbance at 254 nm.    
 
20-50% sucrose gradients were prepared (10 mM Tris pH 7.5, 250 mM KCl, 5 mM MgCl2, 
1 mM DTT, 20U/ml RNAseOUT, 100 µg/ml cyclohexamide) (Biocomp).  Ribosome 
preparation was applied to gradient and centrifuged in ultracentrifuge at 38000 rpm for 2 
hours at 4 oC. 
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Fractions were collected (approximately 1 ml samples) and frozen at -80oC until ready for 
RNA collection (by TrizolLS, Invitrogen).  1 µl of RNA from the input and each fraction 
was electrophorese on a 1% agarose gel to evaluate the quality of the RNA. 
 
RT-qPCR 
750 ng of RNA from each polysome and 1 µg of RNA from inputs was used to synthesize 
cDNA using the VILOkit (Invitrogen).  cDNA was diluted 1 :9 for fractions and 1 :10 for 
input to be used in qPCR as described previously for tubulin, NONO.1, cyclin D1, CGGbp, 
Pim1, and VEGF. 
 
Reporting of polysome RT-qPCR data 
Ct data for inputs alone are presented.  Distribution of mRNA in each polysome fraction is 
reported relative to input.  The percentage of transcripts in each fraction is shown to 
demonstrate the distribution of transcripts in the profile. 
 
Results 
The polysome profile is very similar between the 4ET and E cell lines (see Figure 6.1A and 
6.1B).  The absorbance at 254 nm for 4ET was 0.378 and 0.343 for E.  The profile of the 
RNA extracted for 4ET and E polysomes was also similar.  Superposition of the polysome 
profiles for 4ET and E are almost identical (Figure 6.2). 
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The tubulin in the inputs and the distribution of tubulin in the polysome fractions for 4ET 
and E were very similar (Figure 6.3). 
 
The inputs for transcripts tested all show no difference in raw Cts between 4ET and E 
(Figures 6.4-6.5). 
 
The distribution for 4E-SE containing transcripts across polysomes was similar for 4ET and 
E (Figure 6.6).  The peak of 4ET and E for NONO.1 occurred at fraction #9 and at fraction 
#4 for CGGbp (Figure 6.6A and C).  The peak for cyclin D1 occurred at fraction #6 for 
4ET and fraction #7 for E (Figure 6.6B).   
 
The polysome profile for 4E-sensitive transcript VEGF was nearly identical for 4ET and E 
with a peak at fraction #5 (Figure 6.7A). 
 
The distribution of 4E-SE containing 4E-sensitive transcript Pim1 was very similar for 4ET 
and E with a peak at fraction #6 (Figure 6.7B).  The shape of the distribution of the 4E-SE 
containing 4E-sensitive transcript ODC was also similar for 4ET and E but the peak for 
4ET was at fraction #4 and at fraction #5 for E (Figure 6.7C). 
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Discussion 
Given that the shape of the polysome traces and the pattern of RNA seen in Figure 6.1 and 
6.2, overexpression of 4ET does not have a large effect on global translation.  Therefore, 
the induction of P-bodies in the 4ET cell lines did not result in changes in the polysome 
profile using the polysome preparation method used.  The similarity in tubulin profile for 
4ET and E and inputs also suggests that global loading of tubulin transcript was unaffected 
by 4ET-induced P-body formation. 
 
The initial polysome preparation (input) contains the cytoplasmic fraction of cells.  Since 
P-bodies and SGs are found within the cytoplasm, the input should also contain all 
cytosolic RNPs.  Given that P-bodies contain several proteins (refer to Table 1.5), if they 
remain intact during the fractionation/extraction process, they will likely be “heavy” and 
sediment with the fraction with the most polysomes if at all.  It would be possible to 
identify the fractions in which 4ET protein is found if samples were treated with 10% 
trichloroacetic acid and then subjected to Western blot (Wilusz, 2008). Therefore, I suggest 
that the transcript distribution on polysomes represents the activity of transcripts not 
associated with P-bodies.   
 
The coincident peaks for 4ET and E for transcripts at the same fraction number of 
NONO.1, CGGbp, VEGF, and Pim1 suggest that the loading of ribosomes on these 
transcripts was not altered by the overexpression of 4ET (Figures 6.6 and 6.7).  The shift of 
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peak toward a lower polysome fraction for cyclin D1, and ODC in the 4ET line as 
compared to E suggests that overexpression of 4ET may have had a minor effect on the 
loading of ribosomes on these transcripts (Figures 6.6B and 6.7C).  Since there was 
cytoplasmic enrichment for both cyclin D1 and ODC transcripts (Figure 5.2D and 5.3F), 
4E-T induced P-bodies may have sequestered a proportion of these transcripts to impede 
their association with ribosomes.  As ODC is a translationally-sensitive transcript while 
cyclin D1 is not (refer to Table 5.3), the dependence on 4E for ribosome assembly may be 
irrelevant with respect to the effect of 4ET overexpression on ribosome loading of these 
transcripts.  Similarly, since cyclin D1 transcript does not possess an IRES while ODC 
transcript does (Table 5.3), the 4ET-induced reduction in the loading of ribosomes on these 
transcripts is also independent of the IRES motif.  Western blot data for ODC would help 
solidify the hypothesis that 4ET overexpression affected the translation of ODC. 
 
The overall modest effect of 4ET overexpression on distribution of transcripts tested 
suggests that overexpression of 4ET alone did not dramatically alter the loading of 
ribosomes onto these transcripts to increase or decrease their translation.  Rather, polysome 
profiles suggest no effect on the translation of NONO.1, CGGbp, VEGF, and Pim1 and a 
decrease in translation of cyclin D1 and ODC.  Again, perhaps co-overexpression of other 
P-body protein(s) might have produced a greater effect on the loading of polysomes onto 
transcripts.   
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Cyclin D1 
Since the western blot data for cyclin D1 (Figure 5.4) is at odds with the polysome profile 
for 4ET as compared to E (Figure 6.6B), I suggest the following model:  4ET 
overexpression induces P-body formation in the cytoplasm. However, as the 
overexpression of 4ET is not accompanied by an increase in P-body associated mRNA 
degradation proteins, cyclin D1 transcript accumulates in P-bodies (as seen in its 
cytoplasmic/nuclear distribution; Figure 5.2D).  This accumulation may be due to 4ET 
interacting with cyclin D1 transcript directly or with another protein, via an as yet to be 
determined RNA motif.  P-body formation in 4ET does not alter the polysome profile 
(Figure 6.1) but may reduce the availability of cyclin D1 transcripts that can load ribosomes 
(as seen by a shift in the cyclin D1 transcript profile for 4ET relative to E; Figure 6.6B). 
The overexpressed 4ET protein interacts with cyclin D1 protein (confocal data of Figure 
5.5) to increase its stability, which is seen as a relative increase as compared to E by 
Western blot (Figure 5.4).   
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Figure 6.1.  Polysome profiles and RNA of each faction.  A) 4ET; B) E.  
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Figure 6.2.  Superposition of polysome traces for 4ET and E. 
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Figure 6.3.  Tubulin data.  A) Input Cts; B) polysome profile for tubulin. 
 
 
 
 
 
 
 
Figure 6.4. Raw Ct data for inputs of 4E-SE containing transcripts. A) NONO.1; B) Cyclin 
D1; C) CGGbp.  
 
 
 
 
 
 
Figure 6.5.  Raw Ct data for inputs of 4E-sensitive transcripts and 4E-SE containing 4E-
sensitive transcripts.  A) VEGF (4E-sensitive transcripts); 4E-SE containing 4E-sensitive 
transcripts B) Pim1; C) ODC. 
A. B. 
A. B. C. 
A. B. C. 
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Figure 6.6.  Transcript profiles for 4E-SE containing transcripts.  A) NONO.1; B) Cyclin 
D1; C) CGGbp. 
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Figure 6.7.  Transcript profiles for 4E-sensitive and 4E-SE containing 4E-sensitive 
transcripts.  A) VEGF; B) Pim1; C) ODC. 
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Chapter 7.  General discussion and Conclusion 
The purpose of this memoire was to test the following  hypothesis:  4E-T simultaneously 
modulates the activities of 4E in the nucleus (mRNA export), in the cytosol (translation), 
and in P-bodies (mRNA stability/sequestration) thereby reprogramming the proteome of the 
cell.   
 
The data suggest that 4E-T overexpression alone does not affect 4E-mediated mRNA 
export or translation of most of the targets tested (Chapter 5).  Cyclin D1 and ODC mRNAs 
may be sequestered in P-bodies and their sequestration appears to reduce the efficiency of 
ribosome loading onto these transcripts (Chapters 5 and 6).  The interaction of 4ET with 
cyclin D1 and ODC transcripts (and perhaps others) may be direct or indirect (Figure 8.1).  
By Western blot, I have demonstrated that the translation of most of the targets tested was 
also unaltered (Chapter 5).   
 
Therefore, overexpression of 4ET alone in U2Os cells does not appear to reduce the 
oncogenic potential of 4E in the cell system I generated.  Perhaps overexpression of 4ET in 
a cell line that has endogenously high levels of 4E would have different effects.  My 
attempts to overexpress 4ET in a cell line with high levels of 4E (the squamous cell 
carcinoma FaDu) were unsuccessful.  I have also generated U2Os cell lines that co-
overexpress 4E and 4ET but have not included them in this study.   
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Overexpression of 4ET in a different cell line might yield different results than those shown 
here not only due to 4E levels within the cell, but due to the activity of signaling pathways 
affecting post-translational modifications that affect 4ET function.   
 
As suggested in previous chapters, the co-overexpression of other P-body components (see 
Table 1.6) may be important in more radically effecting P-body mediated changes in the 
proteome. 
 
In all cases of co-overexpression, the balance between the level of 4ET overexpression and 
either 4E and/or P-body protein overexpression may be of critical importance.  Controlling 
overepxression via an inducible promoter is possible but introduces another level of 
complexity in studying the relationship between 4E and 4ET. 
 
Cyclin D1 and Mdm2 
The observation that cyclin D1 protein and Mdm2 protein are elevated in Y30A and 4ET 
was unexpected and may reflect 4ET protein stabilizing these proteins. 
 
Cyclin D1 protein levels change throughout the cell cycle.  Cyclin D1 must be high in G1 
to initiate DNA synthesis, then must be suppressed to low levels in S to allow synthesis.  
Cyclin D1 is degraded in S phase (via proteosomes in response to phophosphorylation at 
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Thr 286 by glycogen synthase kinase-3& (GSK-3&) (Diehl, Cheng, Roussel, & Sherr, 1998) 
and needs to be resynthesized to re-enter G2 (K. Yang, Hitomi, & Stacey, 2006).  Cyclin 
D1 is reduced in the nucleus in many cell types during S phase.  Overexpression of cyclin 
D1 alone is insufficient for oncogenic transformation, rather nuclear trafficking and 
proteolysis is critical for the manifestation of its oncogenicity (Kim & Diehl, 2009).  The 
cyclin box of cyclin D1 is critical for its interaction with Cdk4 and the interaction is critical 
for nuclear transportation of the complex (Murakami, Horihata, Andojo, Yoneda-Kato, & 
Kato, 2009).  Nuclear cyclin D1 overexpression is associated with cell proliferation (Itoi et 
al., 2000). 
 
If cyclin D1 protein is retained in the cytoplasm by 4ET protein, then it could have no 
effect on proliferation despite accumulation.  Sequestration of cyclin D1 in P-bodies may 
impede GSK-3&-cyclin D1 and/or cyclin D1-Cdk4 interactions.  Confirmation of 4ET-
cyclin D1 protein-protein interaction in the 4ET overexpression situation would need to be 
performed first before exploring this line of arguments. 
 
Ectopic expression of cyclin D1 impairs proliferation and enhances apoptosis (Duquesne et 
al., 2001).  A fluorescence-activated cell sorting (FACS) experiment could clarify if 4ET 
overexpression (and observed increase in cyclin D1 protein) affects cell susceptibility to 
apoptosis.  My preliminary FACS data for Y30A and 4ET is inconclusive at present. 
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Mdm2 gene (murine double minute gene 2) encodes an E3 ubiquitin ligase that targets p53 
for proteasome-mediated decay, thereby controlling the level of p53 and affecting 
transformation (Momand, Zambetti, Olson, George, & Levine, 1992). Mdm2 shuttles from 
nucleus to cytoplasm and appears to direct p53 to proteasomes (Kubbutat, Jones, & 
Vousden, 1997).  Since Mdm2 protein is elevated in Y30A and 4ET, it too may be 
sequestered in P-bodies to prevent p53 degradation (analogous to cyclin D1 GSK-3& 
relationship).  Again demonstration of 4ET and Mdm2 protein-protein interaction would 
need to be confirmed. 
 
Future directions 
 
As I have generated a cell line that overexpresses an HA-tagged version of 4ET, it offers 
the possibility to examine RNA and proteins that associate with overexpressed 4ET.   
 
HA-RNAIP could be performed (Hassan, et al., 2010) to confirm the association of cyclin 
D1 and ODC transcripts with 4ET.  The same type of experiment could be expanded to 
recover all transcripts (and possibly miRNA) that associate with 4ET.  Once candidate 
transcripts have been identified, their presence in P-bodies could be confirmed by FISH 
combined with indirect immunofluorescence for 4ET and 4E. As suggested earlier, 
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bioinformatics analysis could help identify sequence and/or secondary structure elements 
common to cyclin D1 and ODC.  If direct interaction of 4ET protein with specific mRNA is 
found to be true, it may be analogous to the 4E-HP-bicoid-caudal mRNA relationship seen 
in Drosophila (Table 7.1). 
 
Immunoprecipitation followed by mass-spectrometry of HA-tagged 4ET could be 
performed to identify other protein partners of 4ET.  As discussed earlier, it may prove 
difficult to isolate enough material to perform such an experiment due to the transient 
nature of P-body components (Leung & Sharp, 2006).  Other challenges in P-body isolation 
could arise due to their molecular mass, low abundance and/or incompletely understood 
physicochemical properties (e.g. high-density hydrophobic proteins such as GW182).  
Special precautions should be considered in the IP such as modified protocols described by 
(Moser, et al., 2009).  Dependence of RNA for 4ET-other protein interactions can then be 
explored experimentally with RNAse. 
 
Protein binding partners of 4ET could interact with specific mRNA elements (Figure 7.1B).  
If this 4E-4ET-protein X-mRNA relationship exists, it joins the list of other cases where 
4E-binding proteins are recruited by specific proteins present only on a subset of mRNAs 
(Table 7.1).   
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Once the RNA motif of cyclin D1 and ODC is identified and the protein domain that binds 
the RNA motif is also identified, this information could be used in cancer therapy.  For 
example, a protein domain that binds specific oncogenic RNA motifs could be fused to a P-
body localization domain to create a chimeric protein that specifically degrades these 
transcripts.  This engineered protein could potentially relieve the burden of excess 
oncogenic transcripts. 
 
Specific overexpression of eIF41b combined with 4ET in cells that have high 4E could also 
be an interesting area of study.  Since eIF41b has strong interaction with 4ET and 
translational repressor properties (Evsikov & Marin de Evsikova, 2009; Minshall, Reiter, 
Weil, & Standart, 2007) their co-overexpression could change the proteome in cells with 
high 4E.  However, as was seen in the present study, it is possible that oncogenic protein 
could accumulate as a consequence (either direct or indirect) of 4ET overexpression. 
 
All of these proposed therapeutic avenues involving 4ET require a thorough understanding 
of the activities of the protein and its interactions with RNA and with proteins.  Therefore, 
further study of 4ET is warranted. 
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Figure 7.1.  Models of potential interaction of 4ET and mRNA in P-bodies.  A) direct 4ET 
interaction of an RNA element (sequence and/or secondary structure); B) indirect 4ET 
interaction (via a to be determined protein). 
 
  
110 
 
Table 8.1.  Examples of 4E-4EBP-protein X-mRNA relationships. (adapted from (Cho et 
al., 2006; Jung, Lorenz, & Richter, 2006; Napoli et al., 2008; Nelson, Leidal, & Smibert, 
2004; Standart & Minshall, 2008) 
Class of 
4E 
4EBP Protein X mRNA  
element 
mRNA 
4E eIF4G PABP polyA Most mRNA 
4E Cup Bruno BRE Drosophila oskar 
4E Cup Smaug SRE Drosophila nanos 
4E-HP Bicoid - BBR Drosophila caudal 
4E-HP Brat Nanos/Pum NRE Drosophila hunchback 
4E Maskin CPEB CPE Xenopus cyclin B1 
eIF4E1b 4ET CPEB CPE Xenopus cyclin 
4E CYFIP1 FMRP unknown Human BC1, Map1b, !CaMKII, 
Arc, App in brain 
4E neuroguidin CPEB CPE unknown 
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Supplemental data 
siRNA depletion of 4ET inhibits P-body formation in FaDu cells. 
 
Introduction 
As a demonstration that 4ET is required for P-body formation, I performed 4ET depletion 
(by siRNA) in FaDu cells (adherent human hypopharyngeal squamous cell carcinoma cell 
line) which has endogenously high 4E (as compared to Detroit 551, Borden lab 
unpublished).   
  
Materials and Methods 
 
FaDu cells (ATCC HTB-43) were grown to 50% confluence and then subjected to siRNA 
treatment by lipofectamine 2000(Invitrogen) as per manufacturer’s instructions  (Mock (no 
siRNA); si4ETC (sense 5’AUCCUGUAUUCAGACAAUGUACACUCC 3’; antisense 5’ 
TAGGACAUAAGUCUGUUACAUGUGA 3’); siLuc (against firefly luciferase; 5’-
CACGUACGCGGAAUACUUCGA-3’).   
 
Indirect immunflourescence was as performed in Chapter 2. 
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Results 
siRNA for specific depletion of 4ET transcript reduced the number of 4ET positive 
cytoplasmic foci in FaDu cells (compare si4ETC to mock and siLuc). 
 
Discussion 
The absence of 4ET-positive cytoplasmic foci upon 4ET transcript depletion suggests that 
it is important for the formation of P-bodies.  Depletion of 4ET protein is efficient by 
Western blot analysis (data not shown).  Indirect immunofluorescence data demonstrating 
absence of Dcp1a-positive bodies upon 4ET depletion would be needed to more strongly 
support the notion that 4ET is important for P-body formation. 
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Figure S.1.  FaDu cells transfected with si4ET do not have P-bodies.   
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